<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:41:42Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:3172311" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:3172311</identifier><datestamp>2011-09-19</datestamp><setSpec>plosone</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
      <journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id>
      <journal-id journal-id-type="publisher-id">plos</journal-id>
      <journal-id journal-id-type="pmc">plosone</journal-id>
      <journal-title-group>
        <journal-title>PLoS ONE</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1932-6203</issn>
      <publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC3172311</article-id>
      <article-id pub-id-type="pmcid">PMC3172311</article-id>
      <article-id pub-id-type="pmc-uid">3172311</article-id>
      <article-id pub-id-type="pmid">21931868</article-id>
      <article-id pub-id-type="pmid">21931868</article-id>
      <article-id pub-id-type="publisher-id">PONE-D-11-14357</article-id>
      <article-id pub-id-type="doi">10.1371/journal.pone.0024925</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Biology</subject>
          <subj-group>
            <subject>Biochemistry</subject>
          </subj-group>
          <subj-group>
            <subject>Genetics</subject>
            <subj-group>
              <subject>Human Genetics</subject>
              <subj-group>
                <subject>Autosomal Recessive</subject>
              </subj-group>
            </subj-group>
            <subj-group>
              <subject>Genetics of Disease</subject>
              <subject>Molecular Genetics</subject>
              <subject>Population Genetics</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Molecular Cell Biology</subject>
          </subj-group>
          <subj-group>
            <subject>Neuroscience</subject>
            <subj-group>
              <subject>Behavioral Neuroscience</subject>
              <subject>Cellular Neuroscience</subject>
              <subject>Cognitive Neuroscience</subject>
              <subject>Developmental Neuroscience</subject>
              <subject>Molecular Neuroscience</subject>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Medicine</subject>
          <subj-group>
            <subject>Anatomy and Physiology</subject>
          </subj-group>
          <subj-group>
            <subject>Clinical Genetics</subject>
          </subj-group>
          <subj-group>
            <subject>Diagnostic Medicine</subject>
            <subj-group>
              <subject>Pathology</subject>
              <subj-group>
                <subject>Clinical Pathology</subject>
                <subj-group>
                  <subject>Molecular Genetics</subject>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Ubiquitin Ligases of the N-End Rule Pathway: Assessment of Mutations in <italic>UBR1</italic> That Cause the Johanson-Blizzard Syndrome</article-title>
        <alt-title alt-title-type="running-head"><italic>UBR1</italic> and Johanson-Blizzard Syndrome</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Hwang</surname>
            <given-names>Cheol-Sang</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
          <xref ref-type="author-notes" rid="fn1">
<sup>Â¤</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sukalo</surname>
            <given-names>Maja</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Batygin</surname>
            <given-names>Olga</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Addor</surname>
            <given-names>Marie-Claude</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brunner</surname>
            <given-names>Han</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Aytes</surname>
            <given-names>Antonio Perez</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mayerle</surname>
            <given-names>Julia</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Song</surname>
            <given-names>Hyun Kyu</given-names>
          </name>
          <xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Varshavsky</surname>
            <given-names>Alexander</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
          <xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zenker</surname>
            <given-names>Martin</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
          <xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref>
          <xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
<label>1</label>
<addr-line>Division of Biology, California Institute of Technology, Pasadena, California, United States of America</addr-line>
</aff>
      <aff id="aff2">
<label>2</label>
<addr-line>Institute of Human Genetics, University Hospital, Magdeburg, Germany</addr-line>
</aff>
      <aff id="aff3">
<label>3</label>
<addr-line>Service de GÃ©nÃ©tique MÃ©dicale, CHUV, Lausanne, Switzerland</addr-line>
</aff>
      <aff id="aff4">
<label>4</label>
<addr-line>Department of Human Genetics, University Medical Center Nijmegen, Nijmegen, The Netherlands</addr-line>
</aff>
      <aff id="aff5">
<label>5</label>
<addr-line>Dismorfologia y Genetica Reproductiva, Grupo de Investigacion en Perinatologia, Instituto de Investigacion Sanitari, Fundacion Hospital La Fe, Valencia, Spain</addr-line>
</aff>
      <aff id="aff6">
<label>6</label>
<addr-line>Department of Gastroenterology and Nutrition, University Hospital, Greifswald, Germany</addr-line>
</aff>
      <aff id="aff7">
<label>7</label>
<addr-line>School of Life Sciences and Biotechnology, Korea University, Seoul, South Korea</addr-line>
</aff>
      <aff id="aff8">
<label>8</label>
<addr-line>Institute of Human Genetics, University Hospital Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany</addr-line>
</aff>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Nordheim</surname>
            <given-names>Alfred</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group>
      <aff id="edit1">University of Tuebingen, Germany</aff>
      <author-notes>
        <corresp id="cor1">* E-mail: <email>avarsh@caltech.edu</email> (AV); <email>martin.zenker@med.ovgu.de</email> (MZ)</corresp>
        <fn fn-type="con">
          <p>Conceived and designed the experiments: CSH MS MCA HB APA JM HKS AV MZ. Performed the experiments: CSH MS OB MCA HB APA. Analyzed the data: CSH MS MCA HB APA JM HKS AV MZ. Contributed reagents/materials/analysis tools: CSH MS MCA HB APA JM HKS AV MZ. Wrote the paper: CSH AV MZ.</p>
        </fn>
        <fn id="fn1" fn-type="current-aff">
          <label>Â¤</label>
          <p>Current address: Department of Life Science, Pohang University of Science and Technology, Pohang, South Korea</p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>13</day>
        <month>9</month>
        <year>2011</year>
      </pub-date>
      <volume>6</volume>
      <issue>9</issue>
      <elocation-id>e24925</elocation-id>
      <history>
        <date date-type="received">
          <day>26</day>
          <month>7</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>19</day>
          <month>8</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Hwang et al.</copyright-statement>
        <copyright-year>2011</copyright-year>
        <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p>
        </license>
      </permissions>
      <abstract>
        <sec>
          <title>Background</title>
          <p>Johanson-Blizzard syndrome (JBS; OMIM 243800) is an autosomal recessive disorder that includes congenital exocrine pancreatic insufficiency, facial dysmorphism with the characteristic nasal wing hypoplasia, multiple malformations, and frequent mental retardation. Our previous work has shown that JBS is caused by mutations in human <italic>UBR1</italic>, which encodes one of the E3 ubiquitin ligases of the N-end rule pathway. The N-end rule relates the regulation of the <italic>in vivo</italic> half-life of a protein to the identity of its N-terminal residue. One class of degradation signals (degrons) recognized by UBR1 are destabilizing N-terminal residues of protein substrates.</p>
        </sec>
        <sec>
          <title>Methodology/Principal Findings</title>
          <p>Most JBS-causing alterations of UBR1 are nonsense, frameshift or splice-site mutations that abolish UBR1 activity. We report here missense mutations of human <italic>UBR1</italic> in patients with milder variants of JBS. These single-residue changes, including a previously reported missense mutation, involve positions in the RING-H2 and UBR domains of UBR1 that are conserved among eukaryotes. Taking advantage of this conservation, we constructed alleles of the yeast <italic>Saccharomyces cerevisiae UBR1</italic> that were counterparts of missense JBS-<italic>UBR1</italic> alleles. Among these yeast Ubr1 mutants, one of them (H160R) was inactive in yeast-based activity assays, the other one (Q1224E) had a detectable but weak activity, and the third one (V146L) exhibited a decreased but significant activity, in agreement with manifestations of JBS in the corresponding JBS patients.</p>
        </sec>
        <sec>
          <title>Conclusions/Significance</title>
          <p>These results, made possible by modeling defects of a human ubiquitin ligase in its yeast counterpart, verified and confirmed the relevance of specific missense <italic>UBR1</italic> alleles to JBS, and suggested that a residual activity of a missense allele is causally associated with milder variants of JBS.</p>
        </sec>
      </abstract>
      <counts>
        <page-count count="10"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>Johanson-Blizzard syndrome (JBS; OMIM 243800) is a rare autosomal recessive genetic disease of multiple congenital malformations. A combination of nasal wing aplasia and exocrine pancreatic insufficiency is particularly characteristic of JBS. Other commonly encountered JBS features include short stature, oligodontia, deafness, scalp defects, hypothyroidism, imperforate anus, genitourinary malformations, and frequent mental retardation <xref rid="pone.0024925-Zenker1" ref-type="bibr">[1]</xref>â<xref rid="pone.0024925-Jones1" ref-type="bibr">[5]</xref>. Our previous work <xref rid="pone.0024925-Zenker3" ref-type="bibr">[6]</xref> and subsequent studies <xref rid="pone.0024925-AlDosari1" ref-type="bibr">[7]</xref>â<xref rid="pone.0024925-Elting1" ref-type="bibr">[9]</xref> have shown that JBS results from homozygous or compound heterozygous mutations in human <italic>UBR1</italic>, which encodes one of the E3 ubiquitin (Ub) ligases of the N-end rule pathway <xref rid="pone.0024925-Kwon1" ref-type="bibr">[10]</xref>, <xref rid="pone.0024925-Kwon2" ref-type="bibr">[11]</xref>. We also found an exocrine pancreatic insufficiency in <italic>Ubr1<sup>â/â</sup></italic> mice that lacked Ubr1, a phenotype similar to but less severe than the pancreatic phenotype of JBS patients that apparently lack active UBR1 <xref rid="pone.0024925-Zenker3" ref-type="bibr">[6]</xref>.</p>
      <p>The N-end rule relates the regulation of the <italic>in vivo</italic> half-life of an intracellular protein to the identity of its N-terminal residue <xref rid="pone.0024925-Bachmair1" ref-type="bibr">[12]</xref>â<xref rid="pone.0024925-Sriram1" ref-type="bibr">[20]</xref>. In eukaryotes, the N-end rule pathway is a part of the Ub system, which mediates protein turnover through the conjugation of Ub, a 76-residue protein, to proteins that contain specific degradation signals (degrons), thereby marking these proteins for degradation by the 26S proteasome <xref rid="pone.0024925-Varshavsky2" ref-type="bibr">[16]</xref>, <xref rid="pone.0024925-Varshavsky3" ref-type="bibr">[17]</xref>, <xref rid="pone.0024925-Hershko1" ref-type="bibr">[21]</xref>â<xref rid="pone.0024925-Hwang1" ref-type="bibr">[27]</xref>. N-terminal degrons recognized by the N-end rule pathway are called N-degrons. The main determinant of an N-degron is a destabilizing N-terminal residue of a protein (<xref ref-type="fig" rid="pone-0024925-g001">Fig. 1A</xref>). Recognition components of the N-end rule pathway are called N-recognins. In eukaryotes, N-recognins are E3 Ub ligases that bind to specific N-degrons <xref rid="pone.0024925-Kwon2" ref-type="bibr">[11]</xref>, <xref rid="pone.0024925-Varshavsky1" ref-type="bibr">[15]</xref>â<xref rid="pone.0024925-Varshavsky3" ref-type="bibr">[17]</xref>, <xref rid="pone.0024925-Xia1" ref-type="bibr">[28]</xref>â<xref rid="pone.0024925-Kwon3" ref-type="bibr">[34]</xref>.</p>
      <fig id="pone-0024925-g001" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0024925.g001</object-id>
        <label>Figure 1</label>
        <caption>
          <title>The mammalian Arg/N-end rule pathway and missense mutations in human <italic>UBR1</italic> that underlie specific cases of the Johanson-Blizzard syndrome (JBS).</title>
          <p>(A) The mammalian N-end rule pathway. N-terminal residues are indicated by single-letter abbreviations for amino acids. Yellow ovals denote the rest of a protein substrate. âPrimaryâ, âsecondaryâ and âtertiaryâ denote mechanistically distinct subsets of destabilizing N-terminal residues (see <xref ref-type="sec" rid="s1">Introduction</xref>). C* denotes oxidized Cys, either Cys-sulfinate or Cys-sulfonate. MetAPs, Met-aminopeptidases. (B) Single-residue mutations in the UBR1 proteins of JBS patients #1 and #2. The positions of mutant residues are indicated both for the original mutations in human UBR1 and for their mimics in <italic>S. cerevisiae</italic>. (C) Same as in B but the mutation in UBR1 of patient #3 (see <xref ref-type="sec" rid="s2">Results</xref>).</p>
        </caption>
        <graphic xlink:href="pone.0024925.g001"/>
      </fig>
      <p>The N-end rule pathway consists of two branches, the Ac/N-end rule and the Arg/N-end rule pathways. The Ac/N-end rule pathway targets proteins containing N<sup>Î±</sup>-terminally acetylated (Nt-acetylated) residues <xref rid="pone.0024925-Varshavsky3" ref-type="bibr">[17]</xref>, <xref rid="pone.0024925-Hwang2" ref-type="bibr">[32]</xref>. It involves the cotranslational Nt-acetylation of nascent proteins <xref rid="pone.0024925-Jrnvall1" ref-type="bibr">[35]</xref>â<xref rid="pone.0024925-Starheim1" ref-type="bibr">[43]</xref> whose N-termini bear either Met or the small uncharged residues Ala, Val, Ser, Thr or Cys. The Arg/N-end rule pathway involves the N-terminal arginylation (Nt-arginylation) of protein substrates and also the targeting of unacetylated destabilizing N-terminal residues (including Arg) by specific E3 N-recognins that contain the evolutionary conserved UBR domain (<xref ref-type="fig" rid="pone-0024925-g001">Fig. 1A</xref>) <xref rid="pone.0024925-Varshavsky2" ref-type="bibr">[16]</xref>, <xref rid="pone.0024925-Varshavsky3" ref-type="bibr">[17]</xref>, <xref rid="pone.0024925-Sriram1" ref-type="bibr">[20]</xref>, <xref rid="pone.0024925-Hwang1" ref-type="bibr">[27]</xref>, <xref rid="pone.0024925-Xia1" ref-type="bibr">[28]</xref>, <xref rid="pone.0024925-Hwang3" ref-type="bibr">[33]</xref>, <xref rid="pone.0024925-Xia2" ref-type="bibr">[44]</xref>â<xref rid="pone.0024925-MattaCamacho1" ref-type="bibr">[49]</xref>. The âprimaryâ destabilizing N-terminal residues Arg, Lys, His, Leu, Phe, Tyr, Trp, and Ile are directly recognized by E3 N-recognins of the Arg/N-end rule pathway, whereas N-terminal Asp, Glu, Asn, Gln, and Cys function as destabilizing residues through their preliminary modifications. These modifications include Nt-arginylation by the Ate1 arginyl-transferase (R-transferase) (<xref ref-type="fig" rid="pone-0024925-g001">Fig. 1A</xref>) <xref rid="pone.0024925-Varshavsky3" ref-type="bibr">[17]</xref>, <xref rid="pone.0024925-Brower1" ref-type="bibr">[46]</xref>, <xref rid="pone.0024925-Wang1" ref-type="bibr">[47]</xref>, <xref rid="pone.0024925-Kwon4" ref-type="bibr">[50]</xref>, <xref rid="pone.0024925-Hu2" ref-type="bibr">[51]</xref>.</p>
      <p>Regulated degradation of specific proteins by the Arg/N-end rule pathway mediates a legion of physiological functions, including the sensing of heme, nitric oxide (NO), oxygen and short peptides; the selective elimination of misfolded proteins; the regulation of DNA repair and cohesion/segregation of chromosomes; the signaling by G proteins; the regulation of peptide import, meiosis, apoptosis, viral and bacterial infections, fat metabolism, cell migration, actin filaments, spermatogenesis, neurogenesis, and cardiovascular development; the functioning of adult organs, including the brain, muscle, testis and pancreas; and the regulation of leaf, shoot and seed development in plants (refs. <xref rid="pone.0024925-Varshavsky1" ref-type="bibr">[15]</xref>â<xref rid="pone.0024925-Mogk1" ref-type="bibr">[19]</xref>, <xref rid="pone.0024925-Hwang1" ref-type="bibr">[27]</xref>, <xref rid="pone.0024925-Hwang2" ref-type="bibr">[32]</xref>, <xref rid="pone.0024925-Brower1" ref-type="bibr">[46]</xref>, <xref rid="pone.0024925-Wang1" ref-type="bibr">[47]</xref>, <xref rid="pone.0024925-Kwon4" ref-type="bibr">[50]</xref>, <xref rid="pone.0024925-Hu2" ref-type="bibr">[51]</xref>â<xref rid="pone.0024925-Dougan1" ref-type="bibr">[53]</xref> and refs. therein).</p>
      <p>In the yeast <italic>Saccharomyces cerevisiae</italic>, the Arg/N-end rule pathway is mediated by the RING-type Ubr1 E3 Ub ligase. The type-1 and type-2 substrate-binding sites of Ubr1 recognize the unmodified basic (Arg, Lys, His) and bulky hydrophobic (Leu, Phe, Tyr, Trp, Ile) N-terminal residues, respectively <xref rid="pone.0024925-Varshavsky2" ref-type="bibr">[16]</xref>, <xref rid="pone.0024925-Varshavsky3" ref-type="bibr">[17]</xref>, <xref rid="pone.0024925-Xia1" ref-type="bibr">[28]</xref>, <xref rid="pone.0024925-Xie1" ref-type="bibr">[30]</xref>, <xref rid="pone.0024925-Hwang3" ref-type="bibr">[33]</xref>. The type-1 binding site of Ubr1 resides in the â¼70-residue UBR domain <xref rid="pone.0024925-Varshavsky2" ref-type="bibr">[16]</xref>, <xref rid="pone.0024925-Tasaki2" ref-type="bibr">[54]</xref> that has been solved at atomic resolution <xref rid="pone.0024925-Sriram1" ref-type="bibr">[20]</xref>, <xref rid="pone.0024925-Choi1" ref-type="bibr">[48]</xref>, <xref rid="pone.0024925-MattaCamacho1" ref-type="bibr">[49]</xref>. In addition to its type-1/2 binding sites, Ubr1 contains substrate-binding sites that recognize internal (non-N-terminal) degrons of proteins that include Cup9, Mgt1, and misfolded proteins <xref rid="pone.0024925-Xia2" ref-type="bibr">[44]</xref>, <xref rid="pone.0024925-Turner1" ref-type="bibr">[52]</xref>, <xref rid="pone.0024925-Du1" ref-type="bibr">[55]</xref>â<xref rid="pone.0024925-Nillegoda1" ref-type="bibr">[60]</xref>. Recent work showed that the Ubr1-based targeting ensemble is a physical complex of the RING-type Ubr1 E3 and the HECT-type Ufd4 E3, together with their cognate E2 enzymes <xref rid="pone.0024925-Metzger1" ref-type="bibr">[26]</xref>, <xref rid="pone.0024925-Hwang1" ref-type="bibr">[27]</xref>, <xref rid="pone.0024925-Hwang4" ref-type="bibr">[56]</xref>. N-recognins of the mammalian Arg/N-end rule pathway comprise at least four E3 Ub ligases, UBR1, UBR2, UBR4 and UBR5, all of which contain a UBR domain <xref rid="pone.0024925-Kwon2" ref-type="bibr">[11]</xref>, <xref rid="pone.0024925-Varshavsky3" ref-type="bibr">[17]</xref>, <xref rid="pone.0024925-Tasaki1" ref-type="bibr">[18]</xref>, <xref rid="pone.0024925-Sriram1" ref-type="bibr">[20]</xref>, <xref rid="pone.0024925-Xia1" ref-type="bibr">[28]</xref>, <xref rid="pone.0024925-Kwon3" ref-type="bibr">[34]</xref>, <xref rid="pone.0024925-Choi1" ref-type="bibr">[48]</xref>, <xref rid="pone.0024925-MattaCamacho1" ref-type="bibr">[49]</xref>, <xref rid="pone.0024925-Tasaki2" ref-type="bibr">[54]</xref>, <xref rid="pone.0024925-Tasaki3" ref-type="bibr">[61]</xref>, <xref rid="pone.0024925-Yang1" ref-type="bibr">[62]</xref>. The 200 kDa mammalian UBR1 and UBR2 are highly sequelogous (similar in sequence <xref rid="pone.0024925-Varshavsky4" ref-type="bibr">[63]</xref>) to each other and to the 225 kDa <italic>S. cerevisiae</italic> Ubr1, but are largely nonsequelogous (outside of their UBR domains) to other N-recognins such as UBR4 and UBR5.</p>
      <p>Given the multiplicity and a partial functional redundancy of mammalian N-recognins, including the sequelogous UBR1 and UBR2 <xref rid="pone.0024925-Tasaki1" ref-type="bibr">[18]</xref>, <xref rid="pone.0024925-Kwon3" ref-type="bibr">[34]</xref>, <xref rid="pone.0024925-An1" ref-type="bibr">[64]</xref>, the Arg/N-end rule pathway is still present (at a lower level of activity) in either JBS patients or <italic>Ubr1<sup>â/â</sup></italic> mice <xref rid="pone.0024925-Zenker3" ref-type="bibr">[6]</xref>, <xref rid="pone.0024925-Kwon2" ref-type="bibr">[11]</xref>. Most of the known JBS-causing changes of human <italic>UBR1</italic> are nonsense, frameshift or splice-site mutations that are either certain or very likely to completely abolish UBR1 activity <xref rid="pone.0024925-Zenker3" ref-type="bibr">[6]</xref>. We report here novel single-residue changes of UBR1 in patients with milder variants of JBS. These changes and one previously reported missense mutation involve amino acid residues that are conserved between the 200-kDa human UBR1 and the 225-kDa <italic>S. cerevisiae</italic> Ubr1 (<xref ref-type="fig" rid="pone-0024925-g001">Fig. 1B, C</xref>). Taking advantage of this evolutionary conservation, we constructed alleles of <italic>S. cerevisiae UBR1</italic> that were counterparts of missense <italic>UBR1</italic> alleles, and examined the resulting Ubr1 proteins for their activity in the <italic>S. cerevisiae</italic> Arg/N-end rule pathway.</p>
    </sec>
    <sec id="s2">
      <title>Results</title>
      <sec id="s2a">
        <title>Clinical findings</title>
        <p>Clinical characteristics of three patients whose <italic>UBR1</italic> mutations were analyzed in this study are summarized in <xref ref-type="table" rid="pone-0024925-t001">Table 1</xref>. All patients represented sporadic cases and were born to healthy unrelated parents of European origin. Patient #1 was a 17 year old female with congenital pancreatic insufficiency and subtle facial signs of JBS (<xref ref-type="fig" rid="pone-0024925-g002">Fig. 2A</xref>). She had a small scalp defect at birth and developed mild sensorineural deafness (â¼30 dB) requiring no hearing aids so far. This patient exhibited mild developmental delay and learning difficulties. She has completed a secondary school with support and is involved in a vocational training program to become âhealth assistantâ. Based on her relatively high (for a JBS patient) mental status and moderate JBS-type physical and physiological anomalies, she was classified as having a mild form of JBS.</p>
        <fig id="pone-0024925-g002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0024925.g002</object-id>
          <label>Figure 2</label>
          <caption>
            <title>JBS patients.</title>
            <p>(A) Patient #1, whose facial appearance is nearly normal. Note the frontal upsweep of the hair and subtle hypoplasia of the nasal wings (minor signs of JBS). (B) Patient #2, a typical facial appearance of JBS, including the aplasia of nasal wings, midface hypoplasia, and a characteristic frontal hair pattern. (C) Patient #3, with a mild hypoplasia of nasal wings. (D) A previously described case of severe JBS, with typical facial features, in which both alleles of <italic>UBR1</italic> were, most likely, null alleles (see <xref ref-type="sec" rid="s2">Results</xref> and ref. <xref rid="pone.0024925-Zenker3" ref-type="bibr">[6]</xref>).</p>
          </caption>
          <graphic xlink:href="pone.0024925.g002"/>
        </fig>
        <table-wrap id="pone-0024925-t001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0024925.t001</object-id>
          <label>Table 1</label>
          <caption>
            <title>Clinical features in JBS patients.</title>
          </caption>
          <alternatives>
            <graphic id="pone-0024925-t001-1" xlink:href="pone.0024925.t001"/>
            <table frame="hsides" rules="groups">
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Patient</td>
                  <td align="left" rowspan="1" colspan="1">Patient #1</td>
                  <td align="left" rowspan="1" colspan="1">Patient #2</td>
                  <td align="left" rowspan="1" colspan="1">Patient #3</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Genotype</td>
                  <td align="left" rowspan="1" colspan="1">p.V122Lp.H774SfsX5</td>
                  <td align="left" rowspan="1" colspan="1">p.H136Rc.2254+2T&gt;C</td>
                  <td align="left" rowspan="1" colspan="1">p.Q1102Ep.R503X</td>
                  <td align="left" rowspan="1" colspan="1">Total(nâ=â58)<xref ref-type="table-fn" rid="nt101">a</xref>
</td>
                  <td align="left" rowspan="1" colspan="1">Biallelic nonsense/frameshift mutations (nâ=â12)<xref ref-type="table-fn" rid="nt102">b</xref>
</td>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Pancreatic insufficiency</td>
                  <td align="left" rowspan="1" colspan="1">+</td>
                  <td align="left" rowspan="1" colspan="1">+</td>
                  <td align="left" rowspan="1" colspan="1">+</td>
                  <td align="left" rowspan="1" colspan="1">49/50 (98%)</td>
                  <td align="left" rowspan="1" colspan="1">12/12 (100%)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Dental defects</td>
                  <td align="left" rowspan="1" colspan="1">+</td>
                  <td align="left" rowspan="1" colspan="1">+</td>
                  <td align="left" rowspan="1" colspan="1">+</td>
                  <td align="left" rowspan="1" colspan="1">27/28 (96%)</td>
                  <td align="left" rowspan="1" colspan="1">6/6 (100%)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Nasal wing hypoplasia</td>
                  <td align="left" rowspan="1" colspan="1">very mild</td>
                  <td align="left" rowspan="1" colspan="1">+</td>
                  <td align="left" rowspan="1" colspan="1">mild</td>
                  <td align="left" rowspan="1" colspan="1">54/55 (98%)</td>
                  <td align="left" rowspan="1" colspan="1">12/12 (100%)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Deafness</td>
                  <td align="left" rowspan="1" colspan="1">mild</td>
                  <td align="left" rowspan="1" colspan="1">+</td>
                  <td align="left" rowspan="1" colspan="1">+</td>
                  <td align="left" rowspan="1" colspan="1">31/45 (69%)</td>
                  <td align="left" rowspan="1" colspan="1">10/11 (91%)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Scalp defect</td>
                  <td align="left" rowspan="1" colspan="1">+</td>
                  <td align="left" rowspan="1" colspan="1">+</td>
                  <td align="left" rowspan="1" colspan="1">+</td>
                  <td align="left" rowspan="1" colspan="1">41/57 (72%)</td>
                  <td align="left" rowspan="1" colspan="1">8/12 (67%)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Hypothyroidism</td>
                  <td align="left" rowspan="1" colspan="1">-</td>
                  <td align="left" rowspan="1" colspan="1">+</td>
                  <td align="left" rowspan="1" colspan="1">-</td>
                  <td align="left" rowspan="1" colspan="1">17/46 (37%)</td>
                  <td align="left" rowspan="1" colspan="1">5/10 (50%)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Short stature</td>
                  <td align="left" rowspan="1" colspan="1">-</td>
                  <td align="left" rowspan="1" colspan="1">+</td>
                  <td align="left" rowspan="1" colspan="1">-</td>
                  <td align="left" rowspan="1" colspan="1">32/38 (84%)</td>
                  <td align="left" rowspan="1" colspan="1">8/9 (89%)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Urogenital anomalies</td>
                  <td align="left" rowspan="1" colspan="1">-</td>
                  <td align="left" rowspan="1" colspan="1">+</td>
                  <td align="left" rowspan="1" colspan="1">-</td>
                  <td align="left" rowspan="1" colspan="1">15/51 (29%)</td>
                  <td align="left" rowspan="1" colspan="1">5/12 (42%)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Imperforate anus</td>
                  <td align="left" rowspan="1" colspan="1">-</td>
                  <td align="left" rowspan="1" colspan="1">+</td>
                  <td align="left" rowspan="1" colspan="1">-</td>
                  <td align="left" rowspan="1" colspan="1">20/58 (34%)</td>
                  <td align="left" rowspan="1" colspan="1">6/12 (50%)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Mental retardation</td>
                  <td align="left" rowspan="1" colspan="1">-</td>
                  <td align="left" rowspan="1" colspan="1">+</td>
                  <td align="left" rowspan="1" colspan="1">-</td>
                  <td align="left" rowspan="1" colspan="1">25/36 (69%)</td>
                  <td align="left" rowspan="1" colspan="1">8/8 (100%)</td>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="nt101">
              <label>a</label>
              <p>Ref. 1;</p>
            </fn>
            <fn id="nt102">
              <label>b</label>
              <p>Ref. 6 and unpublished data.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>Patient #2 was a 14 year old female with a typical clinical picture of severe JBS (<xref ref-type="fig" rid="pone-0024925-g002">Fig. 2B</xref>; <italic>cf</italic>. <xref ref-type="fig" rid="pone-0024925-g002">Fig. 2D</xref>). Her genotype has been reported previously <xref rid="pone.0024925-Zenker3" ref-type="bibr">[6]</xref> (<xref ref-type="fig" rid="pone-0024925-g001">Fig. 1B</xref>). In addition to the typical nasal wing aplasia and congenital pancreatic insufficiency, patient #2 also exhibited scalp defects, anal atresia, renal anomalies, hypothyroidism, severe deafness, oligodontia, and short stature. Her cognitive performance was in the mentally retarded range (IQ 50â60).</p>
        <p>Patient #3 was a 10 year old girl who was diagnosed with mild JBS, based on the presence of pancreatic insufficiency and mild facial anomalies (<xref ref-type="fig" rid="pone-0024925-g002">Fig. 2C</xref>). She was born with a small scalp defect at the vertex and has been wearing hearing aids since she was 4 years old. Many permanent teeth are missing. The girl is attending a special school for children with hearing impairments. Her cognitive level is reported to be in the low normal range. No formal IQ testing has been done so far.</p>
      </sec>
      <sec id="s2b">
        <title>
<italic>UBR1</italic> mutations in JBS patients</title>
        <p>Patients #1â3 were compound <italic>UBR1</italic> heterozygotes. Specifically, each of them carried a missense mutation in one <italic>UBR1</italic> allele and a mutation in the other <italic>UBR1</italic> allele that would be, most likely, a null mutation. Patient #1 was compound heterozygous for the missense mutation c.364G&gt;C (p.V122L) in exon 3 (<xref ref-type="fig" rid="pone-0024925-g001">Fig. 1B</xref>) and a 1 bp duplication (c.2319dupT) in exon 21. The latter <italic>UBR1</italic> mutation resulted in a translational frameshift and a premature stop codon (p.H774SfsX5). Patient #2 was compound heterozygous for the exon 3 missense mutation c.407A&gt;G (p.H136R) in exon 3 (<xref ref-type="fig" rid="pone-0024925-g001">Fig. 1B</xref>) and a mutation at the splice donor site of exon 20 (c.2254+2T&gt;C). The latter mutation is predicted to cause a skipping of the 64-bp exon 20, resulting in a shift of the <italic>UBR1</italic> open reading frame (ORF) and premature stop codon (Mutation Taster: <ext-link ext-link-type="uri" xlink:href="http://www.mutationtaster.org/">www.mutationtaster.org/</ext-link>). Patient #3 carried a missense mutation c.3304C&gt;G (p.Q1102E) in exon 30 of one <italic>UBR1</italic> allele (<xref ref-type="fig" rid="pone-0024925-g001">Fig. 1C</xref>) and a nonsense mutation c.1507C&gt;T (p.R503X) in exon 13 of the other allele.</p>
        <p>A preferential expression of the corresponding missense <italic>UBR1</italic> alleles was observed with patients #1 and #3, whose blood leukocyte RNA samples were available (data not shown), consistent with the (presumed) nonsense-mediated decay (NMD) of mutant <italic>UBR1</italic> mRNAs that were transcribed from the <italic>UBR1</italic> alleles containing the frameshift and nonsense mutations in patients #1 and #3, respectively. Among the three missense alleles of <italic>UBR1</italic>, two of them, V122L (patient #1) and Q1102E (patient #3), are novel (<xref ref-type="fig" rid="pone-0024925-g001">Fig. 1B, C</xref>). The H136R mutation in <italic>UBR1</italic> of patient #2 was described by us previously <xref rid="pone.0024925-Zenker3" ref-type="bibr">[6]</xref>. None of these <italic>UBR1</italic> mutations were found in more than 300 healthy control subjects. The three affected positions in UBR1 proteins of patients #1â3 are sufficiently highly conserved to have unambiguously identifiable counterparts in <italic>S. cerevisiae</italic> Ubr1 and in other eukaryotes as well (<xref ref-type="fig" rid="pone-0024925-g001">Fig. 1B, C</xref>).</p>
        <p>The V122L mutation in patient #1 and the H136R mutation in patient #2 are located in the N-terminus-proximal UBR box of human UBR1 (and <italic>S. cerevisiae</italic> Ubr1), whereas the Q1102E mutation affects the RING-H2 domain in the C-terminal half of Ubr1 (<xref ref-type="fig" rid="pone-0024925-g001">Figs. 1B, C</xref> and <xref ref-type="fig" rid="pone-0024925-g003">3A</xref>). Positions 122, 136 and 1,102 of the human UBR1 protein correspond to positions 146, 160, and 1,224 of <italic>S. cerevisiae</italic> Ubr1 (<xref ref-type="fig" rid="pone-0024925-g001">Fig. 1B, C</xref>). <xref ref-type="fig" rid="pone-0024925-g003">Fig. 3A, B</xref> illustrates the overall organization of the 225 kDa <italic>S. cerevisiae</italic> Ubr1 and the structure of its UBR domain <xref rid="pone.0024925-Choi1" ref-type="bibr">[48]</xref>. This crystal-derived structure of UBR in yeast Ubr1 is highly spalogous (spatially similar <xref rid="pone.0024925-Varshavsky4" ref-type="bibr">[63]</xref>) to the crystal structure of the human UBR domain <xref rid="pone.0024925-Sriram1" ref-type="bibr">[20]</xref>, <xref rid="pone.0024925-MattaCamacho1" ref-type="bibr">[49]</xref>. <xref ref-type="fig" rid="pone-0024925-g003">Fig. 3BâD</xref> illustrates, through molecular modeling, the spatial configurations of locales in the structure of the UBR domain that contain single-residue JBS alterations. These models were produced by mutating specific residues of wild-type UBR1 <italic>in silico</italic> and thereafter choosing rotamers of these residues to minimize steric clashes (<xref ref-type="fig" rid="pone-0024925-g003">Fig. 3C, D</xref>).</p>
        <fig id="pone-0024925-g003" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0024925.g003</object-id>
          <label>Figure 3</label>
          <caption>
            <title>
<italic>S. cerevisiae</italic> Ubr1 N-recognin.</title>
            <p>(A) A diagram of the 225 kDa <italic>S. cerevisiae</italic> Ubr1. The indicated evolutionarily conserved regions of Ubr1 are the UBR box, the BRR (basic residues-rich) domain, the Cys/His-rich RING-H2 domain, and the AI (<underline>a</underline>uto<underline>in</underline>hibitory) domain <xref rid="pone.0024925-Tasaki1" ref-type="bibr">[18]</xref>, <xref rid="pone.0024925-Xie1" ref-type="bibr">[30]</xref>, <xref rid="pone.0024925-Hwang3" ref-type="bibr">[33]</xref>. Three missense mutations in patients #1-3 of the present work are indicated as well (see <xref ref-type="fig" rid="pone-0024925-g001">Fig. 1B, C</xref>). (B) Ribbon diagram of the <italic>S. cerevisiae</italic> UBR domain <xref rid="pone.0024925-Choi1" ref-type="bibr">[48]</xref> in a complex with RLGES, the N-terminal region of the separase-produced fragment of Scc1, a subunit of cohesin <xref rid="pone.0024925-Rao1" ref-type="bibr">[75]</xref>. The bound RLGES peptide is shown as a stick model, with carbon atoms colored yellow. Several residues are marked with a black sphere and numbered to facilitate the tracing of the polypeptide chain. The names of residues of the RLGES peptide are in red, with the letter âsâ (substrate) appended to their position numbers. Side-chains of residues in the UBR domain that are present near JBS mutations (<xref ref-type="fig" rid="pone-0024925-g001">Fig. 1B, C</xref>) are shown in a stick form, with carbon atoms colored green. Three coordinated zinc ions of the UBR domain <xref rid="pone.0024925-Choi1" ref-type="bibr">[48]</xref> are shown as red spheres. (C) Close-up view of the UBR region near the V146L mutation (patient #1; <xref ref-type="fig" rid="pone-0024925-g001">Fig. 1B</xref>). In panel B, this region of UBR is boxed and labeled as âCâ. The residues of UBR that accommodate the position-2 Leu residue (âLeu2sâ) of the RLGES peptide substrate are shown and labeled. The van der Waals sphere of the mutant Leu residue, in the UBR1<sup>V146L</sup> mutant, is shown as purple dots. (D) Close-up view of the UBR region near the H160R mutation (patient #2, <xref ref-type="fig" rid="pone-0024925-g001">Fig. 1B</xref>). In panel B, this region of UBR is boxed and labeled as âDâ. The residues of UBR coordinating Zn3 atom are shown and labeled. The van der Waals sphere of the mutant Arg residue, in the UBR1<sup>H160R</sup> mutant, is shown as purple dots. The views in (C) and (D) are oriented to maximize visibility of mutation-proximal residues.</p>
          </caption>
          <graphic xlink:href="pone.0024925.g003"/>
        </fig>
        <p>The wild-type Val<sup>146</sup> residue of yeast Ubr1 (Val<sup>122</sup> in human UBR1) is located immediately before a short Î²-strand that forms in the UBR domain upon its binding to a peptide with N-terminal Arg (a mimic of N-end rule substrate) (<xref ref-type="fig" rid="pone-0024925-g003">Fig. 3B</xref>). This region of the UBR domain exists as a loop in the absence of a bound peptide <xref rid="pone.0024925-Choi1" ref-type="bibr">[48]</xref>. Because the side chain of Leu is larger than that of Val, the V146L alteration of Ubr1 (<xref ref-type="fig" rid="pone-0024925-g001">Fig. 1B</xref>) is expected to locally perturb UBR conformation, but not in a major way. In <xref ref-type="fig" rid="pone-0024925-g003">Fig. 3C</xref>, the second residue of the UBR-bound peptide is Leu, denoted as âLeu2sâ, i.e., Leu<sup>2</sup> of substrate. One testable possibility is that the V146L mutation decreases the affinity of the UBR domain for type-1 N-end rule substrates with position-2 residues that are bulkier than Leu.</p>
        <p>As to the H160R mutation, i.e. the other missense JBS alteration in the UBR domain, (H136R in human UBR1), its likely functional consequences are more clear and more severe, because wild-type His<sup>160</sup> is one of two histidines and two cysteines that coordinate Zn3, a third zinc ion in the UBR domain (<xref ref-type="fig" rid="pone-0024925-g003">Fig. 3B, D</xref>). A bulky and strongly positively charged residue such as Arg at this position is likely to destabilize coordination of Zn3 (<xref ref-type="fig" rid="pone-0024925-g003">Fig. 3D</xref>). In contrast to the wild-type Ubr1, Ubr1<sup>V146L</sup> and Ubr1<sup>Q1224E</sup> proteins, Ubr1<sup>H160R</sup> was expressed at low steady-state levels both in <italic>S. cerevisiae</italic> and in lymphocytes of patient #2, strongly suggesting its metabolic instability (see below). Finally, although a 3-D structure of the RING-H2 domain, in the C-terminal half of Ubr1 (<xref ref-type="fig" rid="pone-0024925-g003">Fig. 3A</xref>), is unknown, it is likely that the replacement of the highly conserved uncharged Gln<sup>1224</sup> (Gln<sup>1102</sup> in human UBR1) by the charged Glu residue in Ubr1<sup>Q1224E</sup> (<xref ref-type="fig" rid="pone-0024925-g001">Fig. 1C</xref>) would significantly perturb RING-H2 (a Zn-stabilized domain in RING-type E3 Ub ligases <xref rid="pone.0024925-Deshaies1" ref-type="bibr">[24]</xref>, <xref rid="pone.0024925-Bosu1" ref-type="bibr">[65]</xref>, <xref rid="pone.0024925-OConnell1" ref-type="bibr">[66]</xref>. The function of the RING-H2 domain in Ubr1 includes the interaction of this E3 with a cognate E2 enzyme (Rad6 in <italic>S. cerevisiae</italic>, HR6A or HR6B in mammals) <xref rid="pone.0024925-Kwon2" ref-type="bibr">[11]</xref>, <xref rid="pone.0024925-Varshavsky3" ref-type="bibr">[17]</xref>, <xref rid="pone.0024925-Kwon3" ref-type="bibr">[34]</xref>, <xref rid="pone.0024925-Dohmen1" ref-type="bibr">[67]</xref>, <xref rid="pone.0024925-Roest1" ref-type="bibr">[68]</xref>.</p>
      </sec>
      <sec id="s2c">
        <title>Functional testing of <italic>S. cerevisiae</italic> JBS-type Ubr1 mutants</title>
        <p>Low-copy (<italic>CEN</italic>-based) plasmids that expressed the wild-type <italic>S. cerevisiae</italic> Ubr1 and its single-residue mutants Ubr1<sup>V146L</sup>, Ubr1<sup>H160R</sup> and Ubr1<sup>Q1224E</sup> (<xref ref-type="fig" rid="pone-0024925-g001">Fig. 1B, C</xref>) from the native yeast P<italic><sub>UBR1</sub></italic> promoter, were transformed into <italic>ubr1Î</italic> cells that lacked Ubr1 and therefore lacked the Arg/N-end rule pathway. These cells also carried plasmids that expressed the previously characterized X-Î²-galactosidase (X-Î²gal) N-end rule reporters, produced using the Ub fusion technique, i.e. through the cotranslational deubiquitylation, by a family of deubiquitylase enzymes, of Ub-X-Î²gal fusion proteins (Xâ=âHis, Tyr) <xref rid="pone.0024925-Hwang1" ref-type="bibr">[27]</xref>, <xref rid="pone.0024925-Xie1" ref-type="bibr">[30]</xref>â<xref rid="pone.0024925-Hwang2" ref-type="bibr">[32]</xref>, <xref rid="pone.0024925-Varshavsky5" ref-type="bibr">[69]</xref>. The His and Tyr residues of His-Î²gal and Tyr-Î²gal are examples of the type-1 and type-2 primary destabilizing N-terminal residues (<xref ref-type="fig" rid="pone-0024925-g001">Fig. 1A</xref>). These residues are recognized by the corresponding binding sites of Ubr1 (see <xref ref-type="sec" rid="s1">Introduction</xref>). As shown previously, the enzymatic activity of Î²gal in extracts from yeast cells that express an X-Î²gal reporter can serve as a reliable measure of the reporter's metabolic stability <xref rid="pone.0024925-Xie1" ref-type="bibr">[30]</xref>, <xref rid="pone.0024925-Suzuki1" ref-type="bibr">[31]</xref>, <xref rid="pone.0024925-Varshavsky5" ref-type="bibr">[69]</xref>. We chose His and Tyr as the N-terminal residues of X-Î²gal reporters for these assays, instead of, for example, the more âdestabilizingâ type-1 and type-2 N-terminal residues such as Arg or Leu. The moderately destabilizing His (type-1) and Tyr (type-2) residues resulted in a slower degradation of the corresponding N-end rule reporters in wild-type cells, thereby increasing the sensitivity of this assay to changes in Ubr1 activity.</p>
        <p>Steady-state levels of His-Î²gal and Tyr-Î²gal were significantly decreased in cells that expressed wild-type Ubr1, in comparison to their levels in <italic>ubr1Î</italic> cells, owing to degradation of these reporters by the Arg/N-end rule pathway <xref rid="pone.0024925-Hwang1" ref-type="bibr">[27]</xref>, <xref rid="pone.0024925-Xie1" ref-type="bibr">[30]</xref>, <xref rid="pone.0024925-Suzuki1" ref-type="bibr">[31]</xref>, <xref rid="pone.0024925-Varshavsky5" ref-type="bibr">[69]</xref> (<xref ref-type="fig" rid="pone-0024925-g004">Fig. 4A</xref>). Ubr1<sup>H160R</sup>, whose single-residue mutation resides in the UBR domain, in the region of the Zn3 ion coordination that is expected to be strongly perturbed by the change from His to Arg at position 160 (<xref ref-type="fig" rid="pone-0024925-g001">Figs. 1B</xref>, <xref ref-type="fig" rid="pone-0024925-g003">3D</xref>, and discussion above), was completely inactive in conferring metabolic instability on His-Î²gal or Tyr-Î²gal (<xref ref-type="fig" rid="pone-0024925-g004">Fig. 4A</xref>). The absence of detectable activity in Ubr1<sup>H160R</sup> resulted, most likely, from the above structural perturbation but could be also caused, in part, by the metabolic instability of Ubr1<sup>H160R</sup> (see below). The same measurements with Ubr1<sup>Q1224E</sup>, whose single-residue mutation resides in the RING-H2 domain (<xref ref-type="fig" rid="pone-0024925-g001">Figs. 1B, C</xref> and <xref ref-type="fig" rid="pone-0024925-g003">3A</xref>) indicated a much lower than wide-type but reproducibly detectable activity of Ubr1<sup>Q1224E</sup> toward both His-Î²gal and Tyr-Î²gal (<xref ref-type="fig" rid="pone-0024925-g004">Fig. 4A</xref>). Specifically, the levels of these reporters in the presence of Ubr1<sup>Q1224E</sup> were slightly but reproducibly lower than the levels of the same reporters in <italic>ubr1Î</italic> cells that carried empty vector (<xref ref-type="fig" rid="pone-0024925-g004">Fig. 4A</xref>).</p>
        <fig id="pone-0024925-g004" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0024925.g004</object-id>
          <label>Figure 4</label>
          <caption>
            <title>Functional activity of yeast Ubr1 mimics of missense JBS-UBR1 mutants.</title>
            <p>(A) Relative enzymatic activity of Î²gal in extracts from <italic>S. cerevisiae</italic> JD55 (<italic>ubr1Î</italic>) that expressed His-Î²gal or Tyr-Î²gal, and also carried an empty vector, or an otherwise identical plasmid expressing wild-type <italic>S. cerevisiae</italic> Ubr1, or (separately) its three missense mutants Ubr1<sup>V146L</sup>, Ubr1<sup>H160R</sup>, or Ubr1<sup> Q1224E</sup>. The activity of Î²gal was measured in triplicates, with standard deviations shown. (B) Relative levels of induction of the peptide transporter Ptr2 were assayed by measuring the activity of a plasmid-borne <italic>lacZ</italic> (Î²gal-encoding) reporter that was expressed from the P<italic><sub>PTR2</sub></italic> promoter in <italic>ubr1Î S. cerevisiae</italic> that carried either an empty vector or otherwise identical plasmids that expressed either wild-type Ubr1 <xref rid="pone.0024925-Hwang1" ref-type="bibr">[27]</xref>, <xref rid="pone.0024925-Xia1" ref-type="bibr">[28]</xref>, <xref rid="pone.0024925-Turner1" ref-type="bibr">[52]</xref> or its indicated mutants. Cells were grown to A<sub>600</sub> of â¼0.8 in SC(-Ura, -Leu) medium at 30Â°C, followed by measurements, in triplicate, of Î²gal activity in cell extracts, with standard deviations shown. (C) The lysine-requiring JD55 (<italic>ubr1Î</italic>) <italic>S. cerevisiae</italic> strain was grown on plates containing 110 ÂµM lysine (Lys) or 66 ÂµM Lys-Ala dipeptide as the sole source of Lys in the medium <xref rid="pone.0024925-Hwang1" ref-type="bibr">[27]</xref>, <xref rid="pone.0024925-Hwang3" ref-type="bibr">[33]</xref>, <xref rid="pone.0024925-Turner1" ref-type="bibr">[52]</xref>. JD52 (<italic>ubr1Î</italic>) cells carried a vector plasmid or otherwise identical plasmids expressing wild-type Ubr1 or its missense mutants Ubr1<sup>H160R</sup>, Ubr1<sup>V146L</sup> and Ubr1<sup> Q1224E</sup>. Cells were grown to A<sub>600</sub> of â¼1 in SC(-Leu) medium at 30Â°C, washed in sterile water, serially diluted 5-fold, spotted on SC(-Leu, -Lys) plates containing 110 ÂµM Lys or 66 ÂµM Lys-Ala, and incubated at 30Â°C for 3 days. (D) Cell extracts (equal total protein levels) from experiments described in panels A and B were subjected to SDS-PAGE, followed by immunoblotting with affinity-purified anti-Ubr1 antibody (upper panel) and anti-tubulin antibody (a loading control; lower panel). Asterisk indicates a protein that crossreacts with anti-Ubr1 antibody. (E) Extracts from human lymphocytes (equal amounts of total protein) were subjected to SDS-PAGE, followed by immunoblotting with antibody to human UBR1 (see <xref ref-type="sec" rid="s4">Materials and Methods</xref>). Lane 1, wild-type lymphocytes. Lane 2, same as lane 1 but from lymphocytes of patient #2 (see the main text and <xref ref-type="fig" rid="pone-0024925-g001">Figs. 1</xref> and <xref ref-type="fig" rid="pone-0024925-g002">2</xref>). Lane 3, same as lane 1 but with lymphocytes from patient #3. Lane 4, same as lane 1, but with lymphocytes from a JBS patient with a homozygous nonsense mutation in <italic>UBR1</italic>, previously shown to have no detectable UBR1 (null UBR1 control) <xref rid="pone.0024925-Varshavsky3" ref-type="bibr">[17]</xref>. Lane 5, same as a lane 1.</p>
          </caption>
          <graphic xlink:href="pone.0024925.g004"/>
        </fig>
        <p>Ubr1<sup>V146L</sup>, a mimic of the missense JBS mutation in UBR1 of patient #1 (<xref ref-type="fig" rid="pone-0024925-g001">Figs. 1B</xref>, <xref ref-type="fig" rid="pone-0024925-g002">2A</xref>, and <xref ref-type="fig" rid="pone-0024925-g003">3C</xref>), was apparently inactive in conferring metabolic instability on His-Î²gal but exhibited a reproducibly significant activity with Tyr-Î²gal (<xref ref-type="fig" rid="pone-0024925-g004">Fig. 4A</xref>). Ubr1 recognizes N-terminal His, a type-1 destabilizing residue, via its type-1 binding site, which resides in the UBR domain, i.e., the region of mutation in Ubr1<sup>V146L</sup> (<xref ref-type="fig" rid="pone-0024925-g001">Fig. 1B</xref> and <xref ref-type="fig" rid="pone-0024925-g003">Fig. 3B, C</xref>). As discussed above, the severity of perturbation of the UBR domain by this mutation (V146L) is predicted to be lower than the one by H160R. Thus, a parsimonious interpretation of these results is that a functional perturbation of the UBR domain in Ubr1<sup>V146L</sup> abolishes (or nearly abolishes) its activity toward type-1 N-end rule substrates but only impairs (does not abolish) its targeting of type-2 N-end rule substrates, exemplified by Tyr-Î²gal (<xref ref-type="fig" rid="pone-0024925-g004">Fig. 4A</xref>). The N-terminal Tyr residue is recognized by the type-2 site of Ubr1, located downstream of the UBR domain <xref rid="pone.0024925-Varshavsky2" ref-type="bibr">[16]</xref>, <xref rid="pone.0024925-Tasaki1" ref-type="bibr">[18]</xref>, <xref rid="pone.0024925-Mogk1" ref-type="bibr">[19]</xref>, <xref rid="pone.0024925-Xia1" ref-type="bibr">[28]</xref>. In sum, a decreased but significant activity of Ubr1<sup>V146L</sup> in targeting Tyr-Î²gal (<xref ref-type="fig" rid="pone-0024925-g004">Fig. 4A</xref>) is consistent with a lower extent of (expected) perturbation of the UBR domain by this mutation, in comparison to the one in Ubr1<sup>H160R</sup> (<xref ref-type="fig" rid="pone-0024925-g003">Fig. 3BâD</xref>).</p>
        <p>Remarkably, the absence of detectable functional activity in yeast Ubr1<sup>H160R</sup> (the mimic of human UBR1 in patient #2), versus the presence of residual activities in both yeast Ubr1<sup>V146L</sup> and Ubr1 <sup>Q1224E</sup> (the mimics of human UBR1 in patients #1 and #3, respectively) (<xref ref-type="fig" rid="pone-0024925-g004">Fig. 4A</xref>), correlated with a stronger clinical expression of JBS symptoms in patient #2, in comparison to patients #1 and #3 (<xref ref-type="table" rid="pone-0024925-t001">Table 1</xref>, <xref ref-type="fig" rid="pone-0024925-g002">Fig. 2</xref>, and discussion above).</p>
      </sec>
      <sec id="s2d">
        <title>Regulation of peptide import by wild-type and mutant Ubr1 proteins</title>
        <p>The binding of short peptides with destabilizing N-terminal residues to the type-1/2 sites of Ubr1 (see <xref ref-type="sec" rid="s1">Introduction</xref>) allosterically activates the autoinhibited third substrate-binding site of Ubr1 that recognizes an internal degron of Cup9, a transcriptional repressor of roughly 50 genes <xref rid="pone.0024925-Varshavsky3" ref-type="bibr">[17]</xref>, <xref rid="pone.0024925-Hwang3" ref-type="bibr">[33]</xref>, <xref rid="pone.0024925-Xia2" ref-type="bibr">[44]</xref>, <xref rid="pone.0024925-Turner1" ref-type="bibr">[52]</xref>, <xref rid="pone.0024925-Du1" ref-type="bibr">[55]</xref>. Genes that are down-regulated by Cup9 include <italic>PTR2</italic>, which encodes the transporter of di- and tripeptides <xref rid="pone.0024925-Cai1" ref-type="bibr">[70]</xref>. The resulting Ubr1-Cup9-Ptr2 positive-feedback circuit, in which the Ubr1-mediated degradation of the Cup9 repressor is accelerated by type-1/2 peptides that bind to Ubr1, allows <italic>S. cerevisiae</italic> to sense the presence of extracellular peptides and to react by accelerating their uptake through induction of the Ptr2 transporter <xref rid="pone.0024925-Xia2" ref-type="bibr">[44]</xref>, <xref rid="pone.0024925-Turner1" ref-type="bibr">[52]</xref>, <xref rid="pone.0024925-Du1" ref-type="bibr">[55]</xref>. A previously characterized cell growth assay allows comparisons of the efficacies of dipeptide import by congenic <italic>S. cerevisiae</italic> strains <xref rid="pone.0024925-Hwang1" ref-type="bibr">[27]</xref>, <xref rid="pone.0024925-Hwang3" ref-type="bibr">[33]</xref>, <xref rid="pone.0024925-Turner1" ref-type="bibr">[52]</xref>. In this assay, a lysine-requiring <italic>S. cerevisiae</italic> strain is grown on plates containing either lysine (Lys) or the Lys-Ala dipeptide as the sole source of Lys in the medium. To grow under the latter conditions, cells must be capable of a sufficiently efficacious dipeptide import. <italic>ubr1Î S. cerevisiae</italic> carrying either a vector plasmid or otherwise identical plasmids expressing wild-type Ubr1 or its missense mutants Ubr1<sup>H160R</sup>, Ubr1<sup>V146L</sup> and Ubr1 <sup>Q1224E</sup>, were grown in the presence of either Lys or Lys-Ala in the medium (<xref ref-type="fig" rid="pone-0024925-g004">Fig. 4C</xref>). Whereas all examined strains grew in the presence of Lys, only cells expressing wild-type Ubr1 grew on plates containing Lys-Ala instead of Lys (<xref ref-type="fig" rid="pone-0024925-g004">Fig. 4C</xref>).</p>
        <p>In a different assay for peptide import, relative levels of induction of the peptide transporter Ptr2 were assayed by measuring the activity of a <italic>lacZ</italic> (Î²gal-encoding) reporter that was expressed from the P<italic><sub>PTR2</sub></italic> promoter in <italic>ubr1Î S. cerevisiae</italic> that carried either an empty vector or otherwise identical plasmids that expressed wild-type Ubr1 <xref rid="pone.0024925-Hwang1" ref-type="bibr">[27]</xref>, <xref rid="pone.0024925-Xia1" ref-type="bibr">[28]</xref>, <xref rid="pone.0024925-Turner1" ref-type="bibr">[52]</xref> or its missense mutants. In contrast to wild-type Ubr1, which strongly induced the P<italic><sub>PTR2</sub>-lacZ</italic> fusion, both Ubr1<sup>H160R</sup> and Ubr1<sup>Q1224E</sup> mutants did not induce it detectably, i.e., significantly above the level in the presence of vector alone (<xref ref-type="fig" rid="pone-0024925-g004">Fig. 4B</xref>). Interestingly, the Ubr1<sup>V146L</sup> mutant, similarly to its reduced but still significant activity in mediating the <italic>in vivo</italic> degradation of Tyr-Î²gal (<xref ref-type="fig" rid="pone-0024925-g004">Fig. 4A</xref>), exhibited a diminished but significant activity in the P<italic><sub>PTR2</sub></italic>-<italic>lacZ</italic> assay (<xref ref-type="fig" rid="pone-0024925-g004">Fig. 4B</xref>).</p>
        <p>As a part of Ubr1 tests, we also compared the levels of wild-type and mutant Ubr1 proteins that were produced from the native P<italic><sub>UBR1</sub></italic> promoter and low copy plasmids in <italic>ubr1Î S. cerevisiae</italic> (see <xref ref-type="sec" rid="s4">Materials and Methods</xref>). Cell extracts from indicated <italic>S. cerevisiae</italic> transformants were subjected to SDS-PAGE and immunoblotting with the previously characterized, affinity-purified antibody to yeast Ubr1 <xref rid="pone.0024925-Hwang3" ref-type="bibr">[33]</xref>. Similar amounts of Ubr1 and its mutants were produced in yeast transformants that had been employed in experiments of this study, except for Ubr1<sup>H160R</sup>, whose levels were considerably lower than the levels of either wild-type Ubr1, Ubr1<sup>Q1224E</sup> or Ubr1<sup>V146L</sup> (see <xref ref-type="fig" rid="pone-0024925-g004">Fig. 4D</xref> and its legend for details). The Ubr1-expressing plasmids were identical save for single-nucleotide nonsynonymous mutations in the <italic>UBR1</italic> ORF (<xref ref-type="fig" rid="pone-0024925-g001">Fig. 1B, C</xref>). Thus a parsimonious interpretation is that the H160R mutation, which is expected to strongly destabilize the UBR domain (<xref ref-type="fig" rid="pone-0024925-g003">Fig. 3D</xref>) (see discussion above), results, in turn, in a metabolic destabilization and low steady-state levels of the Ubr1<sup>H160R</sup> protein (<xref ref-type="fig" rid="pone-0024925-g004">Fig. 4D</xref>).</p>
        <p>This interpretation is strongly supported by independent evidence, through immunoblotting-based comparisons of the levels of human UBR1 proteins in lymphocytes of JBS patients (<xref ref-type="fig" rid="pone-0024925-g004">Fig. 4E</xref>). Whereas the mutant UBR1 <sup>Q1102E</sup> protein of patient #3 was readily detectable in lymphocytes of this patient, no UBR1 could be detected in otherwise identical extracts from patient #2, whose UBR1 <sup>H136R</sup> was the counterpart of yeast UBR1 <sup>H160R</sup> (<xref ref-type="fig" rid="pone-0024925-g004">Fig. 4E</xref>). We conclude that the absence of detectable Ubr1<sup>H160R</sup> activity <italic>in vivo</italic>, in contrast to Ubr1<sup>Q1224E</sup> and Ubr1<sup>V146L</sup> (<xref ref-type="fig" rid="pone-0024925-g004">Fig. 4A, B</xref>), stemmed, at least in part, from the accelerated <italic>in vivo</italic> degradation of Ubr1<sup>H160R</sup>, in addition to the likely diminished or absent functional activity of this mutant. A precedent for a single missense mutation that could confer a short <italic>in vivo</italic> half-life on yeast Ubr1 was the previously characterized change of its wild-type Tyr<sup>277</sup> to Ala or Glu <xref rid="pone.0024925-Hwang3" ref-type="bibr">[33]</xref>.</p>
      </sec>
    </sec>
    <sec id="s3">
      <title>Discussion</title>
      <p>Mutational inactivation of human UBR1, one of the E3 Ub ligases of the Arg/N-end rule pathway (<xref ref-type="fig" rid="pone-0024925-g001">Fig. 1A</xref>), is the cause of Johanson-Blizzard syndrome (see <xref ref-type="sec" rid="s1">Introduction</xref>) <xref rid="pone.0024925-Zenker1" ref-type="bibr">[1]</xref>, <xref rid="pone.0024925-Zenker2" ref-type="bibr">[2]</xref>, <xref rid="pone.0024925-Zenker3" ref-type="bibr">[6]</xref>, <xref rid="pone.0024925-Varshavsky3" ref-type="bibr">[17]</xref>. Previously studied cases of the typical severe expression of the syndrome involved nonsense, frameshift or splice-site mutations of <italic>UBR1</italic> that were either certain or very likely to completely abolish UBR1 activity <xref rid="pone.0024925-Zenker3" ref-type="bibr">[6]</xref>. The present study of less severe JBS cases and their association with missense mutations in one of two copies of <italic>UBR1</italic> indicates that the relative mildness of symptoms in JBS patients #1 and #3 (<xref ref-type="fig" rid="pone-0024925-g002">Fig. 2A, C</xref>) is most likely caused by a significant residual activity of the corresponding UBR1 mutants (<xref ref-type="fig" rid="pone-0024925-g001">Figs. 1B, C</xref> and <xref ref-type="fig" rid="pone-0024925-g004">4AâC</xref>).</p>
      <p>The mechanistic cause(s) of JBS remains to be understood, in part because all other UBR-type N-recognins, including UBR2 (which is 47% identical to UBR1 <xref rid="pone.0024925-Kwon2" ref-type="bibr">[11]</xref>, <xref rid="pone.0024925-Kwon3" ref-type="bibr">[34]</xref> and is expressed in exocrine pancreas as well) are retained in JBS patients. Their cells, therefore, still contain the Arg/N-end rule pathway. One possibility is that UBR1, despite its strong sequelogy <xref rid="pone.0024925-Varshavsky4" ref-type="bibr">[63]</xref> to UBR2, has a physiological protein substrate(s) that is unique to UBR1. If so, a loss of UBR1 activity (for example, its total loss in severe JBS (<xref ref-type="fig" rid="pone-0024925-g002">Fig. 2D</xref>) <xref rid="pone.0024925-Zenker3" ref-type="bibr">[6]</xref>) would increase the level of a postulated (normally short-lived) substrate(s) and thereby mediate (or contribute to) the broad range of JBS phenotypes, with severity of these phenotypes determined by the levels of residual UBR1 activity in specific cell types of a JBS patient. Alternatively, physiological substrates that are not unique to UBR1 might be involved. Previous work has shown that <italic>S. cerevisiae</italic> Ubr1 is an activity-limiting component of the yeast Arg/N-end rule pathway <xref rid="pone.0024925-Bartel1" ref-type="bibr">[71]</xref>. Thus UBR1 and UBR2 may share all of JBS-relevant physiological substrates but in the absence of UBR1 the efficacy of targeting of such substrates by UBR2 alone might not be high enough, particularly in some cell types. (Expression patterns of mouse <italic>Ubr2</italic> overlap with but are not identical to those of <italic>Ubr1</italic>
<xref rid="pone.0024925-Kwon2" ref-type="bibr">[11]</xref>, <xref rid="pone.0024925-Kwon3" ref-type="bibr">[34]</xref>.)</p>
      <p>It is also possible that a JBS-relevant function of UBR1 is a previously unknown and <italic>a priori</italic> unexpected one. For example, it was recently shown that mouse Ubr2, a strong sequelog of Ubr1 (47% identity in mice), functions to metabolically <italic>stabilize</italic> Tex19.1, a germ cell-specific protein in mouse testis, through a direct interaction between Ubr2 and Tex19.1 <xref rid="pone.0024925-Yang1" ref-type="bibr">[62]</xref>. Metabolic stabilization of Tex19.1 by Ubr2 in wild-type mouse cells is functionally relevant, because both <italic>Tex19.1<sup>â/â</sup></italic> mice and <italic>Ubr2<sup>â/â</sup></italic> mice exhibit similar phenotypes of defective spermatogenesis, and the levels of Tex.19.1 in testis are strongly decreased in the absence of Ubr2 <xref rid="pone.0024925-Yang1" ref-type="bibr">[62]</xref>. It is unknown, at present, whether Ubr1 also binds to and stabilizes Tex19.1. However, it is already clear that at least some N-recognins not only target proteins for degradation but can also bind to and protect specific proteins from degradation <italic>in vivo</italic>
<xref rid="pone.0024925-Varshavsky3" ref-type="bibr">[17]</xref>, <xref rid="pone.0024925-Yang1" ref-type="bibr">[62]</xref>, a circumstance that further increases the range of UBR1 mechanisms that may be relevant to JBS.</p>
      <p>A major lacuna in the current understanding of mammalian N-recognins is the paucity of identified physiological UBR1 substrates. At present, the known (as distinguished from putative) substrates of mammalian UBR1 comprise largely the G-protein regulators RGS4, RGS5 and RGS16, and the separase-produced fragment of the Rad21 cohesin subunit (refs. <xref rid="pone.0024925-Varshavsky2" ref-type="bibr">[16]</xref>, <xref rid="pone.0024925-Varshavsky3" ref-type="bibr">[17]</xref>, <xref rid="pone.0024925-Hu2" ref-type="bibr">[51]</xref>, <xref rid="pone.0024925-Lee1" ref-type="bibr">[72]</xref> and refs. therein). Misfolded proteins are also among physiological substrates of UBR1 and UBR2 in mammals and Ubr1 in yeast, although specific degrons involved remain to be identified <xref rid="pone.0024925-Heck1" ref-type="bibr">[57]</xref>, <xref rid="pone.0024925-Eisele1" ref-type="bibr">[58]</xref>, <xref rid="pone.0024925-Prasad1" ref-type="bibr">[59]</xref>, <xref rid="pone.0024925-Nillegoda1" ref-type="bibr">[60]</xref>. In addition, physiological substrates of <italic>S. cerevisiae</italic> Ubr1 include Cup9 and Mgt1, a transcriptional repressor and a DNA repair protein, respectively (see <xref ref-type="sec" rid="s1">Introduction</xref>). For several reasons <xref rid="pone.0024925-Varshavsky2" ref-type="bibr">[16]</xref>, <xref rid="pone.0024925-Varshavsky3" ref-type="bibr">[17]</xref>, it is highly likely that mammalian UBR1 and other eukaryotic N-recognins have a large number of physiological substrates. Identifying such proteins (<xref ref-type="fig" rid="pone-0024925-g001">Fig. 1A</xref>), with an emphasis on substrates that might be unique for UBR1 (as distinguished, for example, from UBR2), should advance the mechanistic understanding of JBS and its multiple phenotypes.</p>
    </sec>
    <sec sec-type="materials|methods" id="s4">
      <title>Materials and Methods</title>
      <sec id="s4a">
        <title>Patients</title>
        <p>This study was approved by the Local Ethics Committee (University Hospital, Magdeburg, Germany), and informed consent, in writing, was obtained from the parents/patients, including written informed consent for publication of the present data in biomedical journals, including PLoS One. Patients were personally evaluated by a clinical geneticist (M.C.A, A.P.A, H.B.) and their hospital charts were reviewed. These patients are a part of the cohort of 35 unrelated, molecularly confirmed JBS patients that were identified over several years. The criterion for inclusion in this study was the presence of a missense <italic>UBR1</italic> mutation affecting an amino acid residue at a position conserved between human UBR1 and <italic>S. cerevisiae</italic> Ubr1.</p>
      </sec>
      <sec id="s4b">
        <title>Mutations in <italic>UBR1</italic>
</title>
        <p>Genomic DNA was extracted from peripheral blood leukocytes using standard methods. All 47 coding exons of the human <italic>UBR1</italic> gene and flanking intronic regions were amplified by PCR and subjected to bidirectional sequencing using the dye-terminator sequencing method (BigDye Terminator v.3.1; Applied Biosystems) and an automated capillary sequencer ABI 3730 Genetic Analyzer, (Applied Biosystems, Weiterstadt, Germany), as described previously <xref rid="pone.0024925-Zenker3" ref-type="bibr">[6]</xref>.</p>
      </sec>
      <sec id="s4c">
        <title>Yeast strains, plasmids, Î²-galactosidase assays, and immunoblotting</title>
        <p>The <italic>S. cerevisiae</italic> strains used were JD52 (MATa <italic>ura3-52 his3-Î200 leu2-3,112 trp1-Î63 lys2-801 ubr1Î::HIS3</italic>) and JD55 (MATa <italic>ura3-52 his3-Î200 leu2-3,112 trp1-Î63 lys2-801 ubr1Î::HIS3</italic>) <xref rid="pone.0024925-Hwang4" ref-type="bibr">[56]</xref>. The low-copy plasmids were the previously described pRS315 (control vector) and pCH100 (pRS315-UBR1) <xref rid="pone.0024925-Hwang2" ref-type="bibr">[32]</xref>, <xref rid="pone.0024925-Hwang3" ref-type="bibr">[33]</xref>, or the otherwise identical pCH638 (pRS315-UBR1<sup>H160R</sup>), pCH639 (pRS315-UBR1<sup>Q1224E</sup>), and pCH640 (pRS315-UBR1<sup>V146L</sup>) that expressed Ubr1 mutants. The pCH100 plasmid contained only one of the <italic>Stu</italic>I, <italic>Spe</italic>I, <italic>Msc</italic>I and <italic>Mlu</italic>I sites in <italic>S. cerevisiae UBR1</italic>. Overlapping-extension PCR was used to introduce specific mutations (V146L, H160R and Q1224E) into the <italic>UBR1</italic> ORF. A pair of PCR primers, OOM7/OOM8 or OCH56/OCH88 (<xref ref-type="table" rid="pone-0024925-t001">Table 1</xref>), which flanked the region between the <italic>Stu</italic>I and <italic>Spe</italic>I sites, or between the <italic>Msc</italic>I and <italic>Mlu</italic>I sites of <italic>UBR1</italic>, were used to construct V146L, H160R and Q1224E UBR1 mutants. To do so, pCH100 was employed as a PCR template, in conjunction with specific primers (<xref ref-type="table" rid="pone-0024925-t001">Table 1</xref>). The resulting PCR products were digested with <italic>Stu</italic>I/<italic>Spe</italic>I or <italic>Msc</italic>I/<italic>Mlu</italic>I and ligated into <italic>Stu</italic>I/<italic>Spe</italic>I-cut or <italic>Msc</italic>I/<italic>Mlu</italic>I-cut pCH100, yielding the plasmids pCH638, pCH640 and pCH639, respectively.</p>
        <p>Standard yeast techniques and media were employed for strain construction, transformation and growth <xref rid="pone.0024925-Sherman1" ref-type="bibr">[73]</xref>, <xref rid="pone.0024925-Ausubel1" ref-type="bibr">[74]</xref>. Assays for Î²-galactosidase (Î²gal) activity in <italic>S. cerevisiae</italic> extracts were carried out as previously described <xref rid="pone.0024925-Hwang1" ref-type="bibr">[27]</xref>, <xref rid="pone.0024925-Xie1" ref-type="bibr">[30]</xref>, <xref rid="pone.0024925-Suzuki1" ref-type="bibr">[31]</xref>, <xref rid="pone.0024925-Varshavsky5" ref-type="bibr">[69]</xref>, using Yeast Î²-Galactosidase Assay Kit (Thermo scientific, Rockford, IL) and the manufacturer's protocol. Immunoblotting of proteins that had been fractionated by SDS-4â12% NuPAGE was carried out as previously described, using a previously characterized, affinity-purified antibody to <italic>S. cerevisiae</italic> Ubr1 <xref rid="pone.0024925-Hwang1" ref-type="bibr">[27]</xref>, <xref rid="pone.0024925-Hwang2" ref-type="bibr">[32]</xref>, <xref rid="pone.0024925-Hwang4" ref-type="bibr">[56]</xref>. Immunoblotting of extracts from human lymphocytes was carried out using antibody to human UBR1, as previously described <xref rid="pone.0024925-Zenker3" ref-type="bibr">[6]</xref>.</p>
        <p>JD55 (<italic>ubr1Î</italic>) <italic>S. cerevisiae</italic> carried the plasmids pSS4 (P<italic><sub>PTR2</sub>-LacZ</italic>) and either pCH100 (wild-type Ubr1), pCH638 (Ubr1<sup>H160R</sup>), pCH639 (Ubr1<sup>Q1224E</sup>), or pCH640 (Ubr1<sup>V146L</sup>). Cells were grown at 30Â°C in synthetic complete (SC) medium (0.17% yeast nitrogen base, 0.5% ammonium sulfate, 2% glucose, plus a dropout mixture of compounds required by a given auxotrophic strain) to A<sub>600</sub> â¼0.8, followed by the measurements of Î²gal activity in cell extracts.</p>
      </sec>
    </sec>
  </body>
  <back>
    <ack>
      <p>We thank patients and their families for participating in this study, Angelika Diem (University of Erlangen, Germany) for excellent technical assistance, and Brandon Wadas (California Institute of Technology, USA) for helpful comments on the manuscript.</p>
    </ack>
    <fn-group>
      <fn fn-type="COI-statement">
        <p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <p><bold>Funding: </bold>This work was supported by the German Research Foundation (DFG) grant ZE 5242-3 to M.Z. and grant MA 4115/1-3 to J.M.; by the Korea Research Foundation grant 2008-313-C00521 to H.K.S.; by a grant from the March of Dimes Foundation to A.V.; and by the National Institutes of Health (NIH) grants GM031530 and DK039520 to A.V. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="pone.0024925-Zenker1">
        <label>1</label>
        <element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Zenker</surname><given-names>M</given-names></name></person-group>
<year>2008</year>
<article-title>UBR1, the N-end-rule pathway and the Johanson-Blizzard syndrome.</article-title>
<person-group person-group-type="editor"><name><surname>Epstein</surname><given-names>CJ</given-names></name><name><surname>Erickson</surname><given-names>RP</given-names></name><name><surname>Wynshaw-Boris</surname><given-names>A</given-names></name></person-group>
<source>Inborn Errors of Development, 2nd ed</source>
<publisher-loc>Oxford, U.K.</publisher-loc>
<publisher-name>Oxford University Press</publisher-name>
<fpage>1190</fpage>
<lpage>1194</lpage>
</element-citation>
      </ref>
      <ref id="pone.0024925-Zenker2">
        <label>2</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zenker</surname><given-names>M</given-names></name><name><surname>Mayerle</surname><given-names>J</given-names></name><name><surname>Reis</surname><given-names>A</given-names></name><name><surname>Lerch</surname><given-names>MM</given-names></name></person-group>
<year>2006</year>
<article-title>Genetic basis and pancreatic biology of Johanson-Blizzard syndrome.</article-title>
<source>Endocrinol Metabol Clin North Am</source>
<volume>35</volume>
<fpage>243</fpage>
<lpage>253</lpage>
</element-citation>
      </ref>
      <ref id="pone.0024925-Hurst1">
        <label>3</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hurst</surname><given-names>JA</given-names></name><name><surname>Baraitser</surname><given-names>M</given-names></name></person-group>
<year>1989</year>
<article-title>Johanson-Blizzard syndrome.</article-title>
<source>J Med Genet</source>
<volume>26</volume>
<fpage>45</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="pmid">2645405</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Johanson1">
        <label>4</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Johanson</surname><given-names>A</given-names></name><name><surname>Blizzard</surname><given-names>R</given-names></name></person-group>
<year>1971</year>
<article-title>A syndrome of congenital aplasia of the alae nasi, deafness, hypothyroidism, dwarfism, absent permanent teeth, and malabsorption.</article-title>
<source>J Pediatr</source>
<volume>79</volume>
<fpage>982</fpage>
<lpage>987</lpage>
<pub-id pub-id-type="pmid">5171616</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Jones1">
        <label>5</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jones</surname><given-names>NL</given-names></name><name><surname>Hofley</surname><given-names>PM</given-names></name><name><surname>Durie</surname><given-names>PR</given-names></name></person-group>
<year>1994</year>
<article-title>Pathophysiology of the pancreatic defect in Johanson-Blizzard syndrome: a disorder of acinar development.</article-title>
<source>J Pediatr</source>
<volume>125</volume>
<fpage>406</fpage>
<lpage>408</lpage>
<pub-id pub-id-type="pmid">8071749</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Zenker3">
        <label>6</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zenker</surname><given-names>M</given-names></name><name><surname>Mayerle</surname><given-names>J</given-names></name><name><surname>Lerch</surname><given-names>MM</given-names></name><name><surname>Tagariello</surname><given-names>A</given-names></name><name><surname>Zerres</surname><given-names>K</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>Deficiency of UBR1, a ubiquitin ligase of the N-end rule pathway, causes pancreatic dysfunction, malformations and mental retardation (Johanson-Blizzard syndrome).</article-title>
<source>Nat Genet</source>
<volume>37</volume>
<fpage>1345</fpage>
<lpage>1350</lpage>
<pub-id pub-id-type="pmid">16311597</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-AlDosari1">
        <label>7</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Al-Dosari</surname><given-names>MS</given-names></name><name><surname>Al-Muhsen</surname><given-names>S</given-names></name><name><surname>Al-Jazaeri</surname><given-names>A</given-names></name><name><surname>Mayerle</surname><given-names>J</given-names></name><name><surname>Zenker</surname><given-names>M</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Johanson-Blizzard syndrome: report of a novel mutation and severe liver involvement.</article-title>
<source>Am J Med Genet</source>
<volume>146A</volume>
<fpage>1875</fpage>
<lpage>1879</lpage>
<pub-id pub-id-type="pmid">18553553</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Alkhouri1">
        <label>8</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alkhouri</surname><given-names>N</given-names></name><name><surname>Kaplan</surname><given-names>B</given-names></name><name><surname>Kay</surname><given-names>M</given-names></name><name><surname>Shealy</surname><given-names>A</given-names></name><name><surname>Crowe</surname><given-names>C</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Johanson-Blizzard syndrome with mild phenotypic features confirmed by UBR1 gene testing.</article-title>
<source>World J Gastroenterol</source>
<volume>14</volume>
<fpage>6863</fpage>
<lpage>6866</lpage>
<pub-id pub-id-type="pmid">19058315</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Elting1">
        <label>9</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Elting</surname><given-names>M</given-names></name><name><surname>Kariminejad</surname><given-names>A</given-names></name><name><surname>de Sonnaville</surname><given-names>ML</given-names></name><name><surname>Ottenkamp</surname><given-names>J</given-names></name><name><surname>Bauhuber</surname><given-names>S</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Johanson-Blizzard syndrome caused by identical UBR1 mutations in two unrelated girls, one with a cardiomyopathy.</article-title>
<source>Am J Med Genet</source>
<volume>146A</volume>
<fpage>3058</fpage>
<lpage>3061</lpage>
<pub-id pub-id-type="pmid">19006206</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Kwon1">
        <label>10</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kwon</surname><given-names>YT</given-names></name><name><surname>Reiss</surname><given-names>Y</given-names></name><name><surname>Fried</surname><given-names>VA</given-names></name><name><surname>Hershko</surname><given-names>A</given-names></name><name><surname>Yoon</surname><given-names>JK</given-names></name><etal/></person-group>
<year>1998</year>
<article-title>The mouse and human genes encoding the recognition component of the N-end rule pathway.</article-title>
<source>Proc Natl Acad Sci USA</source>
<volume>95</volume>
<fpage>7898</fpage>
<lpage>7903</lpage>
<pub-id pub-id-type="pmid">9653112</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Kwon2">
        <label>11</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kwon</surname><given-names>YT</given-names></name><name><surname>Xia</surname><given-names>Z</given-names></name><name><surname>Davydov</surname><given-names>IV</given-names></name><name><surname>Lecker</surname><given-names>SH</given-names></name><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group>
<year>2001</year>
<article-title>Construction and analysis of mouse strains lacking the ubiquitin ligase UBR1 (E3-alpha) of the N-end rule pathway.</article-title>
<source>Mol Cell Biol</source>
<volume>21</volume>
<fpage>8007</fpage>
<lpage>8021</lpage>
<pub-id pub-id-type="pmid">11689692</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Bachmair1">
        <label>12</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bachmair</surname><given-names>A</given-names></name><name><surname>Finley</surname><given-names>D</given-names></name><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group>
<year>1986</year>
<article-title>
<italic>In vivo</italic> half-life of a protein is a function of its amino-terminal residue.</article-title>
<source>Science</source>
<volume>234</volume>
<fpage>179</fpage>
<lpage>186</lpage>
<pub-id pub-id-type="pmid">3018930</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Bachmair2">
        <label>13</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bachmair</surname><given-names>A</given-names></name><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group>
<year>1989</year>
<article-title>The degradation signal in a short-lived protein.</article-title>
<source>Cell</source>
<volume>56</volume>
<fpage>1019</fpage>
<lpage>1032</lpage>
<pub-id pub-id-type="pmid">2538246</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Gonda1">
        <label>14</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gonda</surname><given-names>DK</given-names></name><name><surname>Bachmair</surname><given-names>A</given-names></name><name><surname>WÃ¼nning</surname><given-names>I</given-names></name><name><surname>Tobias</surname><given-names>JW</given-names></name><name><surname>Lane</surname><given-names>WS</given-names></name><etal/></person-group>
<year>1989</year>
<article-title>Universality and structure of the N-end rule.</article-title>
<source>J Biol Chem</source>
<volume>264</volume>
<fpage>16700</fpage>
<lpage>16712</lpage>
<pub-id pub-id-type="pmid">2506181</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Varshavsky1">
        <label>15</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group>
<year>1996</year>
<article-title>The N-end rule: functions, mysteries, uses.</article-title>
<source>Proc Natl Acad Sci USA</source>
<volume>93</volume>
<fpage>12142</fpage>
<lpage>12149</lpage>
<pub-id pub-id-type="pmid">8901547</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Varshavsky2">
        <label>16</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group>
<year>2008</year>
<article-title>Discovery of cellular regulation by protein degradation.</article-title>
<source>J Biol Chem</source>
<volume>283</volume>
<fpage>34469</fpage>
<lpage>34489</lpage>
<pub-id pub-id-type="pmid">18708349</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Varshavsky3">
        <label>17</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group>
<year>2011</year>
<article-title>The N-end rule pathway and regulation by proteolysis.</article-title>
<source>Prot Sci</source>
<volume>20</volume>
<fpage>1298</fpage>
<lpage>1345</lpage>
</element-citation>
      </ref>
      <ref id="pone.0024925-Tasaki1">
        <label>18</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tasaki</surname><given-names>T</given-names></name><name><surname>Kwon</surname><given-names>YT</given-names></name></person-group>
<year>2007</year>
<article-title>The mammalian N-end rule pathway: new insights into its components and physiological roles.</article-title>
<source>Trends Biochem Sci</source>
<volume>32</volume>
<fpage>520</fpage>
<lpage>528</lpage>
<pub-id pub-id-type="pmid">17962019</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Mogk1">
        <label>19</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mogk</surname><given-names>A</given-names></name><name><surname>Schmidt</surname><given-names>R</given-names></name><name><surname>Bukau</surname><given-names>B</given-names></name></person-group>
<year>2007</year>
<article-title>The N-end rule pathway of regulated proteolysis: prokaryotic and eukaryotic strategies.</article-title>
<source>Trends Cell Biol</source>
<volume>17</volume>
<fpage>165</fpage>
<lpage>172</lpage>
<pub-id pub-id-type="pmid">17306546</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Sriram1">
        <label>20</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sriram</surname><given-names>SM</given-names></name><name><surname>Kwon</surname><given-names>YT</given-names></name></person-group>
<year>2010</year>
<article-title>The structural basis of N-end rule recognition.</article-title>
<source>Nat Struct Mol Biol</source>
<volume>17</volume>
<fpage>1164</fpage>
<lpage>1165</lpage>
<pub-id pub-id-type="pmid">20924402</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Hershko1">
        <label>21</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hershko</surname><given-names>A</given-names></name><name><surname>Ciechanover</surname><given-names>A</given-names></name><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group>
<year>2000</year>
<article-title>The ubiquitin system.</article-title>
<source>Nat Med</source>
<volume>10</volume>
<fpage>1073</fpage>
<lpage>1081</lpage>
</element-citation>
      </ref>
      <ref id="pone.0024925-Finley1">
        <label>22</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Finley</surname><given-names>D</given-names></name></person-group>
<year>2009</year>
<article-title>Recognition and processing of ubiquitin-protein conjugates by the proteasome.</article-title>
<source>Annu Rev Biochem</source>
<volume>78</volume>
<fpage>477</fpage>
<lpage>513</lpage>
<pub-id pub-id-type="pmid">19489727</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Dye1">
        <label>23</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dye</surname><given-names>BT</given-names></name><name><surname>Schulman</surname><given-names>BA</given-names></name></person-group>
<year>2007</year>
<article-title>Structural mechanisms underlying posttranslational modification by ubiquitin-like proteins.</article-title>
<source>Annu Rev Biophys Biomol Struct</source>
<volume>36</volume>
<fpage>131</fpage>
<lpage>150</lpage>
<pub-id pub-id-type="pmid">17477837</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Deshaies1">
        <label>24</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deshaies</surname><given-names>RJ</given-names></name><name><surname>Joazeiro</surname><given-names>CAP</given-names></name></person-group>
<year>2009</year>
<article-title>RING domain E3 ubiquitin ligases.</article-title>
<source>Annu Rev Biochem</source>
<volume>78</volume>
<fpage>399</fpage>
<lpage>434</lpage>
<pub-id pub-id-type="pmid">19489725</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Frster1">
        <label>25</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>FÃ¶rster</surname><given-names>F</given-names></name><name><surname>Lasker</surname><given-names>K</given-names></name><name><surname>Nickell</surname><given-names>S</given-names></name><name><surname>Sali</surname><given-names>A</given-names></name><name><surname>Baumeister</surname><given-names>W</given-names></name></person-group>
<year>2010</year>
<article-title>Toward an integrated structural model of the 26S proteasome.</article-title>
<source>Mol Cell Proteomics</source>
<volume>9</volume>
<fpage>1666</fpage>
<lpage>1677</lpage>
<pub-id pub-id-type="pmid">20467039</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Metzger1">
        <label>26</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Metzger</surname><given-names>MB</given-names></name><name><surname>Weissman</surname><given-names>AM</given-names></name></person-group>
<year>2010</year>
<article-title>Working on a chain: E3s ganging up for ubiquitylation.</article-title>
<source>Nat Cell Biol</source>
<fpage>1124</fpage>
<lpage>1126</lpage>
<pub-id pub-id-type="pmid">21124306</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Hwang1">
        <label>27</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hwang</surname><given-names>C-S</given-names></name><name><surname>Shemorry</surname><given-names>A</given-names></name><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group>
<year>2010</year>
<article-title>The N-end rule pathway is mediated by a complex of the RING-type Ubr1 and HECT-type Ufd4 ubiquitin ligases.</article-title>
<source>Nat Cell Biol</source>
<volume>12</volume>
<fpage>1177</fpage>
<lpage>1185</lpage>
<pub-id pub-id-type="pmid">21076411</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Xia1">
        <label>28</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xia</surname><given-names>Z</given-names></name><name><surname>Webster</surname><given-names>A</given-names></name><name><surname>Du</surname><given-names>F</given-names></name><name><surname>Piatkov</surname><given-names>K</given-names></name><name><surname>Ghislain</surname><given-names>M</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Substrate-binding sites of UBR1, the ubiquitin ligase of the N-end rule pathway.</article-title>
<source>J Biol Chem</source>
<volume>283</volume>
<fpage>24011</fpage>
<lpage>24028</lpage>
<pub-id pub-id-type="pmid">18566452</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Ravid1">
        <label>29</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ravid</surname><given-names>T</given-names></name><name><surname>Hochstrasser</surname><given-names>M</given-names></name></person-group>
<year>2008</year>
<article-title>Diversity of degradation signals in the ubiquitin-proteasome system.</article-title>
<source>Nat Rev Mol Cell Biol</source>
<volume>9</volume>
<fpage>679</fpage>
<lpage>689</lpage>
<pub-id pub-id-type="pmid">18698327</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Xie1">
        <label>30</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group>
<year>1999</year>
<article-title>The E2-E3 interaction in the N-end rule pathway: the RING-H2 finger of E3 is required for the synthesis of multiubiquitin chain.</article-title>
<source>EMBO J</source>
<volume>18</volume>
<fpage>6832</fpage>
<lpage>6844</lpage>
<pub-id pub-id-type="pmid">10581257</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Suzuki1">
        <label>31</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group>
<year>1999</year>
<article-title>Degradation signals in the lysine-asparagine sequence space.</article-title>
<source>EMBO J</source>
<volume>18</volume>
<fpage>6017</fpage>
<lpage>6026</lpage>
<pub-id pub-id-type="pmid">10545113</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Hwang2">
        <label>32</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hwang</surname><given-names>C-S</given-names></name><name><surname>Shemorry</surname><given-names>A</given-names></name><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group>
<year>2010</year>
<article-title>N-terminal acetylation of cellular proteins creates specific degradation signals.</article-title>
<source>Science</source>
<volume>327</volume>
<fpage>973</fpage>
<lpage>977</lpage>
<pub-id pub-id-type="pmid">20110468</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Hwang3">
        <label>33</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hwang</surname><given-names>C-S</given-names></name><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group>
<year>2008</year>
<article-title>Regulation of peptide import through phosphorylation of Ubr1, the ubiquitin ligase of the N-end rule pathway.</article-title>
<source>Proc Natl Acad Sci USA</source>
<volume>105</volume>
<fpage>19188</fpage>
<lpage>19193</lpage>
<pub-id pub-id-type="pmid">19033468</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Kwon3">
        <label>34</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kwon</surname><given-names>YT</given-names></name><name><surname>Xia</surname><given-names>ZX</given-names></name><name><surname>An</surname><given-names>JY</given-names></name><name><surname>Tasaki</surname><given-names>T</given-names></name><name><surname>Davydov</surname><given-names>IV</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>Female lethality and apoptosis of spermatocytes in mice lacking the UBR2 ubiquitin ligase of the N-end rule pathway.</article-title>
<source>Mol Cell Biol</source>
<volume>23</volume>
<fpage>8255</fpage>
<lpage>8271</lpage>
<pub-id pub-id-type="pmid">14585983</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Jrnvall1">
        <label>35</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>JÃ¶rnvall</surname><given-names>H</given-names></name></person-group>
<year>1975</year>
<article-title>Acetylation of protein N-terminal amino groups: structural observations on alpha-amino acetylated proteins.</article-title>
<source>J Theor Biol</source>
<volume>55</volume>
<fpage>1</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="pmid">1207150</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Mullen1">
        <label>36</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mullen</surname><given-names>JR</given-names></name><name><surname>Kayne</surname><given-names>PS</given-names></name><name><surname>Moerschell</surname><given-names>RP</given-names></name><name><surname>Tsunasawa</surname><given-names>S</given-names></name><name><surname>Gribskov</surname><given-names>M</given-names></name><etal/></person-group>
<year>1989</year>
<article-title>Identification and characterization of genes and mutants for an N-terminal acetyltransferase from yeast.</article-title>
<source>EMBO J</source>
<volume>8</volume>
<fpage>2067</fpage>
<lpage>2075</lpage>
<pub-id pub-id-type="pmid">2551674</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Park1">
        <label>37</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Park</surname><given-names>EC</given-names></name><name><surname>Szostak</surname><given-names>JW</given-names></name></person-group>
<year>1992</year>
<article-title>ARD1 and NAT1 proteins form a complex that has N-terminal acetyltransferase activity.</article-title>
<source>EMBO J</source>
<volume>11</volume>
<fpage>2087</fpage>
<lpage>2093</lpage>
<pub-id pub-id-type="pmid">1600941</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Gautschi1">
        <label>38</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gautschi</surname><given-names>M</given-names></name><name><surname>Just</surname><given-names>S</given-names></name><name><surname>Mun</surname><given-names>A</given-names></name><name><surname>Ross</surname><given-names>S</given-names></name><name><surname>RÃ¼cknagel</surname><given-names>P</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>The yeast N-alpha-acetyltransferase NatA is quantitatively anchored to the ribosome and interacts with nascent polypeptides.</article-title>
<source>Mol Cell Biol</source>
<volume>23</volume>
<fpage>7403</fpage>
<lpage>7414</lpage>
<pub-id pub-id-type="pmid">14517307</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Song1">
        <label>39</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>O-K</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Waterborg</surname><given-names>JH</given-names></name><name><surname>Sternglanz</surname><given-names>R</given-names></name></person-group>
<year>2003</year>
<article-title>An N-alpha-acetyltransferase responsible for acetylation of the N-terminal residues of histones H4 and H2A.</article-title>
<source>J Biol Chem</source>
<volume>278</volume>
<fpage>38109</fpage>
<lpage>38112</lpage>
<pub-id pub-id-type="pmid">12915400</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Arnesen1">
        <label>40</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arnesen</surname><given-names>T</given-names></name><name><surname>Van Damme</surname><given-names>P</given-names></name><name><surname>Polevoda</surname><given-names>B</given-names></name><name><surname>Helsens</surname><given-names>K</given-names></name><name><surname>Evjenth</surname><given-names>R</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Proteomics analyses reveal the evolutionary conservation and divergence of N-terminal acetyltransferases from yeast to humans.</article-title>
<source>Proc Natl Acad Sci USA</source>
<volume>106</volume>
<fpage>8157</fpage>
<lpage>8162</lpage>
<pub-id pub-id-type="pmid">19420222</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Polevoda1">
        <label>41</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Polevoda</surname><given-names>B</given-names></name><name><surname>Sherman</surname><given-names>F</given-names></name></person-group>
<year>2003</year>
<article-title>N-terminal acetyltransferases and sequence requirements for N-terminal acetylation of eukaryotic proteins.</article-title>
<source>J Mol Biol</source>
<volume>325</volume>
<fpage>595</fpage>
<lpage>622</lpage>
<pub-id pub-id-type="pmid">12507466</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Goetze1">
        <label>42</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goetze</surname><given-names>S</given-names></name><name><surname>Qeli</surname><given-names>E</given-names></name><name><surname>Mosimann</surname><given-names>C</given-names></name><name><surname>Staes</surname><given-names>A</given-names></name><name><surname>Gerrits</surname><given-names>B</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Identification and functional characterization of N-terminally acetylated proteins in Drosophila melanogaster.</article-title>
<source>PLoS Biol</source>
<volume>7</volume>
<fpage>e1000236</fpage>
<pub-id pub-id-type="pmid">19885390</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Starheim1">
        <label>43</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Starheim</surname><given-names>KK</given-names></name><name><surname>Gromyko</surname><given-names>D</given-names></name><name><surname>Evjens</surname><given-names>E</given-names></name><name><surname>Ryningen</surname><given-names>A</given-names></name><name><surname>Varhaug</surname><given-names>JE</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Knockdown of human N-alpha-terminal acetyltransferase complex C leads to p53-dependent apoptosis and aberrant human Arl8b localization.</article-title>
<source>Mol Cell Biol</source>
<volume>29</volume>
<fpage>3569</fpage>
<lpage>3581</lpage>
<pub-id pub-id-type="pmid">19398576</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Xia2">
        <label>44</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xia</surname><given-names>Z</given-names></name><name><surname>Turner</surname><given-names>GC</given-names></name><name><surname>Hwang</surname><given-names>C-S</given-names></name><name><surname>Byrd</surname><given-names>C</given-names></name><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group>
<year>2008</year>
<article-title>Amino acids induce peptide uptake via accelerated degradation of CUP9, the transcriptional repressor of the PTR2 peptide transporter.</article-title>
<source>J Biol Chem</source>
<volume>283</volume>
<fpage>28958</fpage>
<lpage>28968</lpage>
<pub-id pub-id-type="pmid">18708352</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Hu1">
        <label>45</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hu</surname><given-names>R-G</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Xia</surname><given-names>Z</given-names></name><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group>
<year>2008</year>
<article-title>The N-end rule pathway is a sensor of heme.</article-title>
<source>Proc Natl Acad Sci USA</source>
<volume>105</volume>
<fpage>76</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="pmid">18162538</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Brower1">
        <label>46</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brower</surname><given-names>CS</given-names></name><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group>
<year>2009</year>
<article-title>Ablation of arginylation in the mouse N-end rule pathway: loss of fat, higher metabolic rate, damaged spermatogenesis, and neurological perturbations.</article-title>
<source>PLoS ONE</source>
<volume>4</volume>
<fpage>e7757</fpage>
<pub-id pub-id-type="pmid">19915679</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Wang1">
        <label>47</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Piatkov</surname><given-names>KI</given-names></name><name><surname>Brower</surname><given-names>CS</given-names></name><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group>
<year>2009</year>
<article-title>Glutamine-specific N-terminal amidase, a component of the N-end rule pathway.</article-title>
<source>Mol Cell</source>
<volume>34</volume>
<fpage>686</fpage>
<lpage>695</lpage>
<pub-id pub-id-type="pmid">19560421</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Choi1">
        <label>48</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Choi</surname><given-names>WS</given-names></name><name><surname>Jeong</surname><given-names>B-C</given-names></name><name><surname>Joo</surname><given-names>YJ</given-names></name><name><surname>Lee</surname><given-names>M-R</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>Structural basis for the recognition of N-end rule substrates by the UBR box of ubiquitin ligases.</article-title>
<source>Nat Struct Mol Biol</source>
<volume>17</volume>
<fpage>1175</fpage>
<lpage>1181</lpage>
<pub-id pub-id-type="pmid">20835240</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-MattaCamacho1">
        <label>49</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matta-Camacho</surname><given-names>E</given-names></name><name><surname>Kozlov</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>FF</given-names></name><name><surname>Gehring</surname><given-names>K</given-names></name></person-group>
<year>2010</year>
<article-title>Structural basis of substrate recognition and specificity in the N-end rule pathway.</article-title>
<source>Nat Struct Mol Biol</source>
<volume>17</volume>
<fpage>1182</fpage>
<lpage>1188</lpage>
<pub-id pub-id-type="pmid">20835242</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Kwon4">
        <label>50</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kwon</surname><given-names>YT</given-names></name><name><surname>Kashina</surname><given-names>AS</given-names></name><name><surname>Davydov</surname><given-names>IV</given-names></name><name><surname>Hu</surname><given-names>R-G</given-names></name><name><surname>An</surname><given-names>JY</given-names></name><etal/></person-group>
<year>2002</year>
<article-title>An essential role of N-terminal arginylation in cardiovascular development.</article-title>
<source>Science</source>
<volume>297</volume>
<fpage>96</fpage>
<lpage>99</lpage>
<pub-id pub-id-type="pmid">12098698</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Hu2">
        <label>51</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hu</surname><given-names>R-G</given-names></name><name><surname>Sheng</surname><given-names>J</given-names></name><name><surname>Xin</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Takahashi</surname><given-names>TT</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>The N-end rule pathway as a nitric oxide sensor controlling the levels of multiple regulators.</article-title>
<source>Nature</source>
<volume>437</volume>
<fpage>981</fpage>
<lpage>986</lpage>
<pub-id pub-id-type="pmid">16222293</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Turner1">
        <label>52</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Turner</surname><given-names>GC</given-names></name><name><surname>Du</surname><given-names>F</given-names></name><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group>
<year>2000</year>
<article-title>Peptides accelerate their uptake by activating a ubiquitin-dependent proteolytic pathway.</article-title>
<source>Nature</source>
<volume>405</volume>
<fpage>579</fpage>
<lpage>583</lpage>
<pub-id pub-id-type="pmid">10850718</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Dougan1">
        <label>53</label>
        <element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Dougan</surname><given-names>DMD</given-names></name><name><surname>Truscott</surname><given-names>KN</given-names></name></person-group>
<year>2011</year>
<article-title>The N-end rule pathway: from recognition by N-recognins, to destruction by AAA+ proteases.</article-title>
<publisher-name>Biochim Biophys Acta (in press)</publisher-name>
</element-citation>
      </ref>
      <ref id="pone.0024925-Tasaki2">
        <label>54</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tasaki</surname><given-names>T</given-names></name><name><surname>Zakrzewska</surname><given-names>A</given-names></name><name><surname>Dudgeon</surname><given-names>D</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Lazo</surname><given-names>JS</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>The substrate recognition domains of the N-end rule pathway.</article-title>
<source>J Biol Chem</source>
<volume>284</volume>
<fpage>1884</fpage>
<lpage>1895</lpage>
<pub-id pub-id-type="pmid">19008229</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Du1">
        <label>55</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Du</surname><given-names>F</given-names></name><name><surname>Navarro-Garcia</surname><given-names>F</given-names></name><name><surname>Xia</surname><given-names>Z</given-names></name><name><surname>Tasaki</surname><given-names>T</given-names></name><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group>
<year>2002</year>
<article-title>Pairs of dipeptides synergistically activate the binding of substrate by ubiquitin ligase through dissociation of its autoinhibitory domain.</article-title>
<source>Proc Natl Acad Sci USA</source>
<volume>99</volume>
<fpage>14110</fpage>
<lpage>14115</lpage>
<pub-id pub-id-type="pmid">12391316</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Hwang4">
        <label>56</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hwang</surname><given-names>C-S</given-names></name><name><surname>Shemorry</surname><given-names>A</given-names></name><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group>
<year>2009</year>
<article-title>Two proteolytic pathways regulate DNA repair by co-targeting the Mgt1 alkyguanine transferase.</article-title>
<source>Proc Natl Acad Sci USA</source>
<volume>106</volume>
<fpage>2142</fpage>
<lpage>2147</lpage>
<pub-id pub-id-type="pmid">19164530</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Heck1">
        <label>57</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Heck</surname><given-names>JW</given-names></name><name><surname>Cheung</surname><given-names>SK</given-names></name><name><surname>Hampton</surname><given-names>RY</given-names></name></person-group>
<year>2010</year>
<article-title>Cytoplasmic protein quality control degradation mediated by parallel actions of the E3 ubiquitin ligases Ubr1 and San1.</article-title>
<source>Proc Natl Acad Sci USA</source>
<volume>107</volume>
<fpage>1106</fpage>
<lpage>1111</lpage>
<pub-id pub-id-type="pmid">20080635</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Eisele1">
        <label>58</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eisele</surname><given-names>F</given-names></name><name><surname>Wolf</surname><given-names>DH</given-names></name></person-group>
<year>2008</year>
<article-title>Degradation of misfolded proteins in the cytoplasm by the ubiquitin ligase Ubr1.</article-title>
<source>FEBS Lett</source>
<volume>582</volume>
<fpage>4143</fpage>
<lpage>4146</lpage>
<pub-id pub-id-type="pmid">19041308</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Prasad1">
        <label>59</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prasad</surname><given-names>R</given-names></name><name><surname>Kawaguchi</surname><given-names>S</given-names></name><name><surname>Ng</surname><given-names>DTW</given-names></name></person-group>
<year>2010</year>
<article-title>A nucleus-based quality control mechanism for cytosolic proteins.</article-title>
<source>Mol Biol Cell</source>
<volume>21</volume>
<fpage>2117</fpage>
<lpage>2127</lpage>
<pub-id pub-id-type="pmid">20462951</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Nillegoda1">
        <label>60</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nillegoda</surname><given-names>NB</given-names></name><name><surname>Theodoraki</surname><given-names>MA</given-names></name><name><surname>Mandal</surname><given-names>AK</given-names></name><name><surname>Mayo</surname><given-names>KJ</given-names></name><name><surname>Ren</surname><given-names>HY</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>Ubr1 and Ubr2 function in a quality control pathway for degradation of unfolded cytosolic proteins.</article-title>
<source>Mol Biol Cell</source>
<volume>21</volume>
<fpage>2102</fpage>
<lpage>2116</lpage>
<pub-id pub-id-type="pmid">20462952</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Tasaki3">
        <label>61</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tasaki</surname><given-names>T</given-names></name><name><surname>Mulder</surname><given-names>LCF</given-names></name><name><surname>Iwamatsu</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>MJ</given-names></name><name><surname>Davydov</surname><given-names>IV</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>A family of mammalian E3 ubiquitin ligases that contain the UBR box motif and recognize N-degrons.</article-title>
<source>Mol Cell Biol</source>
<volume>25</volume>
<fpage>7120</fpage>
<lpage>7136</lpage>
<pub-id pub-id-type="pmid">16055722</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Yang1">
        <label>62</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>An</surname><given-names>JY</given-names></name><name><surname>Kwon</surname><given-names>YT</given-names></name><name><surname>Eckardt</surname><given-names>S</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>The ubiquitin ligase Ubr2, a recognition E3 component of the N-end rule pathway, stabilizes Tex.19.1 during spermatogenesis.</article-title>
<source>PLoS One</source>
<volume>5</volume>
<fpage>e14017</fpage>
<pub-id pub-id-type="pmid">21103378</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Varshavsky4">
        <label>63</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group>
<year>2004</year>
<article-title>Spalog and sequelog: neutral terms for spatial and sequence similarity.</article-title>
<source>Curr Biol</source>
<volume>14</volume>
<fpage>R181</fpage>
<lpage>R183</lpage>
<pub-id pub-id-type="pmid">15028230</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-An1">
        <label>64</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>An</surname><given-names>JY</given-names></name><name><surname>Seo</surname><given-names>JW</given-names></name><name><surname>Tasaki</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>MJ</given-names></name><name><surname>Varshavsky</surname><given-names>A</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Impaired neurogenesis and cardiovascular development in mice lacking the E3 ubiquitin ligases UBR1 and UBR2 of the N-end rule pathway.</article-title>
<source>Proc Natl Acad Sci USA</source>
<volume>103</volume>
<fpage>6212</fpage>
<lpage>6217</lpage>
<pub-id pub-id-type="pmid">16606826</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Bosu1">
        <label>65</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bosu</surname><given-names>DR</given-names></name><name><surname>Kipreos</surname><given-names>ET</given-names></name></person-group>
<year>2008</year>
<article-title>Cullin-RING ubiquitin ligases: global regulation and activation cycles.</article-title>
<source>Cell Div</source>
<volume>3</volume>
<fpage>7</fpage>
<pub-id pub-id-type="pmid">18282298</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-OConnell1">
        <label>66</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O'Connell</surname><given-names>BC</given-names></name><name><surname>Harper</surname><given-names>JW</given-names></name></person-group>
<year>2007</year>
<article-title>Ubiquitin proteasome system (UPS): what can chromatin do for you?</article-title>
<source>Curr Op Cell Biol</source>
<volume>19</volume>
<fpage>206</fpage>
<lpage>214</lpage>
<pub-id pub-id-type="pmid">17314036</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Dohmen1">
        <label>67</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dohmen</surname><given-names>RJ</given-names></name><name><surname>Madura</surname><given-names>K</given-names></name><name><surname>Bartel</surname><given-names>B</given-names></name><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group>
<year>1991</year>
<article-title>The N-end rule is mediated by the UBC2 (RAD6) ubiquitin-conjugating enzyme.</article-title>
<source>Proc Natl Acad Sci USA</source>
<volume>88</volume>
<fpage>7351</fpage>
<lpage>7355</lpage>
<pub-id pub-id-type="pmid">1651502</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Roest1">
        <label>68</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Roest</surname><given-names>HP</given-names></name><name><surname>Baarends</surname><given-names>WM</given-names></name><name><surname>de Wit</surname><given-names>J</given-names></name><name><surname>van Klaveren</surname><given-names>JW</given-names></name><name><surname>Wassenaar</surname><given-names>E</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>The ubiquitin-conjugating DNA repair enzyme HR6A is a maternal factor essential for early embryonic development in mice.</article-title>
<source>Mol Cell Biol</source>
<volume>24</volume>
<fpage>5485</fpage>
<lpage>5495</lpage>
<pub-id pub-id-type="pmid">15169909</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Varshavsky5">
        <label>69</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group>
<year>2005</year>
<article-title>Ubiquitin fusion technique and related methods.</article-title>
<source>Meth Enzymol</source>
<volume>399</volume>
<fpage>777</fpage>
<lpage>799</lpage>
<pub-id pub-id-type="pmid">16338395</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Cai1">
        <label>70</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cai</surname><given-names>H</given-names></name><name><surname>Kauffman</surname><given-names>S</given-names></name><name><surname>Naider</surname><given-names>F</given-names></name><name><surname>Becker</surname><given-names>JM</given-names></name></person-group>
<year>2006</year>
<article-title>Genomewide screen reveals a wide regulatory network for di/tripeptide utilization in Saccharomyces cerevisiae.</article-title>
<source>Genetics</source>
<volume>172</volume>
<fpage>1459</fpage>
<lpage>1476</lpage>
<pub-id pub-id-type="pmid">16361226</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Bartel1">
        <label>71</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bartel</surname><given-names>B</given-names></name><name><surname>WÃ¼nning</surname><given-names>I</given-names></name><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group>
<year>1990</year>
<article-title>The recognition component of the N-end rule pathway.</article-title>
<source>EMBO J</source>
<volume>9</volume>
<fpage>3179</fpage>
<lpage>3189</lpage>
<pub-id pub-id-type="pmid">2209542</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Lee1">
        <label>72</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>MJ</given-names></name><name><surname>Tasaki</surname><given-names>T</given-names></name><name><surname>Moroi</surname><given-names>K</given-names></name><name><surname>An</surname><given-names>JY</given-names></name><name><surname>Kimura</surname><given-names>S</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>RGS4 and RGS5 are in vivo substrates of the N-end rule pathway.</article-title>
<source>Proc Natl Acad Sci USA</source>
<volume>102</volume>
<fpage>15030</fpage>
<lpage>15035</lpage>
<pub-id pub-id-type="pmid">16217033</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Sherman1">
        <label>73</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sherman</surname><given-names>F</given-names></name></person-group>
<year>1991</year>
<article-title>Getting started with yeast.</article-title>
<source>Meth Enzymol</source>
<volume>194</volume>
<fpage>3</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="pmid">2005794</pub-id></element-citation>
      </ref>
      <ref id="pone.0024925-Ausubel1">
        <label>74</label>
        <element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Ausubel</surname><given-names>FM</given-names></name><name><surname>Brent</surname><given-names>R</given-names></name><name><surname>Kingston</surname><given-names>RE</given-names></name><name><surname>Moore</surname><given-names>DD</given-names></name><name><surname>Smith</surname><given-names>JA</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Current Protocols in Molecular Biology.</article-title>
<publisher-loc>New York</publisher-loc>
<publisher-name>Wiley-Interscience</publisher-name>
</element-citation>
      </ref>
      <ref id="pone.0024925-Rao1">
        <label>75</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rao</surname><given-names>H</given-names></name><name><surname>Uhlmann</surname><given-names>F</given-names></name><name><surname>Nasmyth</surname><given-names>K</given-names></name><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group>
<year>2001</year>
<article-title>Degradation of a cohesin subunit by the N-end rule pathway is essential for chromosome stability.</article-title>
<source>Nature</source>
<volume>410</volume>
<fpage>955</fpage>
<lpage>960</lpage>
<pub-id pub-id-type="pmid">11309624</pub-id></element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>